Клинические рекомендации Евразийской Ассоциации Кардиологов (ЕАК)/ Национального общества по изучению сердечной недостаточности и заболеваний миокарда (НОИСН) по диагностике и лечению хронической сердечной недостаточности (2024)

Целью настоящего руководства является содействие врачам-кардиологам в ведении пациентов с хронической сердечной недостаточностью (СН) в соответствии с имеющейся современной доказательной базой. Настоящее руководство содержит данные по диагностике, лечению, реабилитации пациентов с хронической сердечной недостаточностью и данные по острой декомпенсации сердечной недостаточности.

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368

2. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o. Eur J Heart Fail 2021;23:352–80. https://doi.org/10.1002/ejhf.2115

3. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction. J Am Coll Cardiol 2020;76:719–34. https://doi.org/10.1016/j.jacc.2020.05.075

4. Фомин ИВ. Артериальная гипертония в Российской Федерации – последние 10 лет. Что дальше? Сердце: журнал для практикующих врачей. 2007;3(6):120-123. [Fomin I.V. Arterial hypertension in the Russian Federation – the last 10 years. What's next? Heart: a magazine for medical practitioners. 2007;3(6):120-123. (in Russ.)]

5. Ситникова М.Ю., Лясникова Е.А., Юрченко А.В., Трукшина М.А., Либис Р.А., КондратенкО В.Ю., Дупляков Д.В., Хохлунов С.М., Шляхто Е.В. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология 2015;10:5– 13. https://doi.org/10.18565/cardio.2015.10.5-13

6. Поляков Д.С., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г., Бадин Ю.В., Бакулина Е.В., Виноградова Н.Г., Галявич А.С., Ионова Т.С., Камалов Г.М., Кечеджиева С.Г., Козиолова Н.А., Маленкова В.Ю., Мальчикова С.В., Мареев Ю.В., Смирнова Е.А., Тарловская Е.И., Щербинина Е.В., Якушин С.С. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14. https://doi.org/10.18087/cardio.2021.4.n1628

7. Cleland J. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442–63. https://doi.org/10.1016/S0195668X(02)00823-0

8. Lam CSP, Solomon SD. The middle child in heart failure: heart failure with midrange ejection fraction (40–50%). Eur J Heart Fail 2014;16:1049–55. https:// doi.org/10.1002/ejhf.159

9. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230–9. https://doi.org/10.1002/ejhf.1149

10. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019;381:1609–20. https://doi.org/10.1056/NEJMoa1908655

11. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction. Eur J Heart Fail 2017;19:1624–34. https://doi.org/10.1002/ejhf.945

12. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. Circ Hear Fail 2017 Jun;10(6):e003875. https:// doi.org/10.1161/CIRCHEARTFAILURE.117.003875

13. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Hear Fail 2016;4:464–72. https://doi.org/10.1016/j.jchf.2016.02.017

14. Агеев Ф.Т., Овчинников А.Г. Диастолическая сердечная недостаточность: 20 лет спустя. Актуальные вопросы патогенеза, диагностики и лечения сердечной недостаточности с сохраненной ФВ ЛЖ. Кардиология. 2023;63(3):3-12. https://doi.org/10.18087/cardio.2023.3.n2376

15. Терещенко С. Н., Жиров И. В., Нарусов О. Ю., Мареев Ю. В., Затейщиков Д.А., Осмоловская Ю. Ф., Овчинников А. Г., Самко А. Н., Насонова С. Н., Стукалова О. В., Саидова М. А., Скворцов А. А., Шариат М. А. ЮИС. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический бюллетень 2016:2(11):3–33.

16. McMurray JJV. Systolic Heart Failure. N Engl J Med 2010;362:228–38. https://doi.org/10.1056/NEJMcp0909392

17. Chen J, Normand S-LT, Wang Y, Krumholz HM. National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008. JAMA 2011;306:1669. https://doi.org/10.1001/jama.2011.1474

18. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, et al. Hospitalizations After Heart Failure Diagnosis. J Am Coll Cardiol 2009;54:1695–702. https://doi.org/10.1016/j.jacc.2009.08.019

19. Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC Hear Fail 2016;4:808–15. https://doi.org/10.1016/j.jchf.2016.05.001

20. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004;43:317–27. https://doi.org/10.1016/j.jacc.2003.07.046

21. Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 2014;173:163–9. https://doi.org/10.1016/j.ijcard.2014.02.018

22. Cowie M. Hospitalization of patients with heart failure. A population-based study. Eur Heart J 2002;23:877–85. https://doi.org/10.1053/euhj.2001.2973

23. McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999;138:87–94. https://doi.org/10.1016/S0002-8703(99)70251-6

24. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. Circulation 2015;131:269–79. https://doi.org/10.1161/CIRCULATIONAHA.114.010637

25. Rosch S, Kresoja K-P, Besler C, Fengler K, Schöber AR, von Roeder M, et al. Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. Circulation 2022;146:506–18. https://doi.org/10.1161/CIRCULATIONAHA.122.059280

26. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 2020;41:1249–57. https://doi.org/10.1093/eurheartj/ehz550

27. Stewart S, Playford D, Scalia GM, Currie P, Celermajer DS, Prior D, et al. Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men. Eur J Heart Fail 2021;23:406–16. https://doi.org/10.1002/ejhf.2047

28. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65–75. https://doi.org/10.1093/eurheartj/ehi555

29. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, et al. Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. Circ Hear Fail 2011;4:27–35. https://doi.org/10.1161/CIRCHEARTFAILURE.109.932996

30. Ketchum ES, Levy WC. Establishing Prognosis in Heart Failure: A Multimarker Approach. Prog Cardiovasc Dis 2011;54:86–96. https://doi.org/10.1016/j.pcad.2011.03.003

31. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107–15. https://doi.org/10.1161/01.CIR.88.1.107

32. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. https://doi.org/10.15829/1560-4071-2016-8-7-13

33. Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281–91. https://doi.org/10.1093/eurjhf/hfn046

34. Allen LA, Felker GM, Pocock S, McMurray JJV, Pfeffer MA, Swedberg K, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170–7. https://doi.org/10.1093/eurjhf/hfn031

35. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009;374:543–50. https://doi.org/10.1016/S0140-6736(09)61378-7

36. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. J Am Coll Cardiol 2007;50:40–7. https://doi.org/10.1016/j.jacc.2007.02.067

37. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Hear Fail 2014;1:4–25. https://doi.org/10.1002/ehf2.12005

38. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics—2016 Update. Circulation 2016;133. https://doi.org/10.1161/CIR.0000000000000350

39. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the Impact of Heart Failure in the United States. Circ Hear Fail 2013;6:606–19. https://doi.org/10.1161/HHF.0b013e318291329a

40. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. Circulation 2012;126:65–75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770

41. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction. Circulation 2009;119:3070–7. https://doi.org/10.1161/CIRCULATIONAHA.108.815944

42. Paulus WJ, Tschöpe C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2013;62:263–71. https://doi.org/10.1016/j.jacc.2013.02.092

43. Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med 2017;376:896–7. https://doi.org/10.1056/NEJMc1615918

44. Paulus WJ, Dal Canto E. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC Hear Fail 2018;6:1–7. https://doi.org/10.1016/j.jchf.2017.07.012

45. Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, et al. Epidemiology of Heart Failure with Preserved Ejection Fraction. Curr Heart Fail Rep 2014;11:354–65. https://doi.org/10.1007/s11897-014-0223-7

46. Liu M, Fang F, Yu C-M. Noncardiac Comorbidities in Heart Failure With Preserved Ejection Fraction – A Commonly Ignored Fact. Circ J 2015;79:954–9. https://doi.org/10.1253/circj.CJ-15-0056

47. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591–602. https://doi.org/10.1038/nrcardio.2017.65

48. Davie A. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335–9. https://doi.org/10.1093/qjmed/90.5.335

49. Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess (Rockv) 2009 Jul;13(32):1-207 https://doi.org/10.3310/hta13320

50. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011;13:518–27. https://doi.org/10.1093/eurjhf/hfr021

51. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006;11:95– 107. https://doi.org/10.1007/s10741-006-9481-0

52. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KGM, et al. The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure. Circulation 2011;124:2865–73. https://doi.org/10.1161/CIRCULATIONAHA.111.019216

53. Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, et al. Characterization of a Novel Symptom of Advanced Heart Failure: Bendopnea. JACC Hear Fail 2014;2:24–31. https://doi.org/10.1016/j.jchf.2013.07.009

54. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–31. https://doi.org/10.1002/ejhf.1494

55. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ V., et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910–h910. https://doi.org/10.1136/bmj.h910

56. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537–41. https://doi.org/10.1016/j.ejheart.2005.01.022

57. Fuat A, Murphy JJ, Hungin APS, Curry J, Mehrzad AA, Hetherington A, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327–33. PMID: 16638247.

58. Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000;6:194–200. https://doi.org/10.1054/jcaf.2000.9676

59. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349–53. https://doi.org/10.1016/S0140-6736(97)06031-5

60. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001;111:274–9. https://doi.org/10.1016/S0002-9343(01)00841-5

61. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical Utility of Three B-Type Natriuretic Peptide Assays for the Initial Diagnostic Assessment of New Slow-Onset Heart Failure. J Card Fail 2011;17:729–34. https://doi.org/10.1016/j.cardfail.2011.04.013

62. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386–91. https://doi.org/10.1016/S0735-1097(00)01157-8

63. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study. Am J Kidney Dis 2003;41:571–9. https://doi.org/10.1053/ajkd.2003.50118

64. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129–200. https://doi.org/10.1093/eurheartj/ehw128

65. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816–29. https://doi.org/10.1093/eurheartj/ehs224

66. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, et al. Iron status in patients with chronic heart failure. Eur Heart J 2013;34:827–34. https://doi.org/10.1093/eurheartj/ehs377

67. Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35:455–69. https://doi.org/10.1093/eurheartj/eht386

68. Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J 2014;35:416–8. https://doi.org/10.1093/eurheartj/eht515

69. Desai AS. Hyperkalemia in patients with heart failure: Incidence, prevalence, and management. Curr Heart Fail Rep 2009;6:272–80. https://doi.org/10.1007/s11897-009-0037-1

70. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes. J Am Coll Cardiol 2009;54:422–8. https://doi.org/10.1016/j.jacc.2009.04.049

71. van Riet EES, Hoes AW, Limburg A, Landman MAJ, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772–7. https://doi.org/10.1002/ejhf.110

72. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TRD, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222–222. https://doi.org/10.1136/bmj.312.7025.222

73. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002;112:437–45. https://doi.org/10.1016/S0002-9343(02)01048-3

74. Spinarová L. Changes in the ECG in chronic heart failure and after transplantation. Vnitr Lek 2003;49:730–3.

75. Baldasseroni S, Gentile A, Gorini M, Marchionni N, Marini M, Masotti G, et al. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). Ital Heart J 2003;4:607–13. PMID: 14635378.

76. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–50. https://doi.org/10.1093/eurheartj/ehm037

77. Marwick TH, Raman S V., Carrió I, Bax JJ. Recent Developments in Heart Failure Imaging. JACC Cardiovasc Imaging 2010;3:429–39. https://doi.org/10.1016/j.jcmg.2010.02.002

78. Dokainish H, Nguyen JS, Bobek J, Goswami R, Lakkis NM. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. Eur J Echocardiogr 2011;12:857–64. https://doi.org/10.1093/ejechocard/jer157

79. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in Heart Failure. J Am Coll Cardiol 2007;50:381–96. https://doi.org/10.1016/j.jacc.2007.03.048

80. Nagueh SF, Bhatt R, Vivo RP, Krim SR, Sarvari SI, Russell K, et al. Echocardiographic Evaluation of Hemodynamics in Patients With Decompensated Systolic Heart Failure. Circ Cardiovasc Imaging 2011;4:220–7. https://doi.org/10.1161/CIRCIMAGING.111.963496

81. Caballero L, Kou S, Dulgheru R, Gonjilashvili N, Athanassopoulos GD, Barone D, et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Hear J - Cardiovasc Imaging 2015. https://doi.org/10.1093/ehjci/jev083

82. Garbi M, McDonagh T, Cosyns B, Bucciarelli-Ducci C, Edvardsen T, Kitsiou A, et al. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Hear J - Cardiovasc Imaging 2015;16:147–53. https://doi.org/10.1093/ehjci/jeu299

83. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003

84. Tanaka H, Nabeshima Y, Kitano T, Nagumo S, Tsujiuchi M, Ebato M, et al. Optimal timing of echocardiography for heart failure inpatients in Japanese institutions: OPTIMAL Study. ESC Hear Fail 2020;7:4213–21. https://doi.org/10.1002/ehf2.13050

85. Voigt J-U, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging. J Am Soc Echocardiogr 2015;28:183–93. https://doi.org/10.1016/j.echo.2014.11.003

86. Poppe KK, Doughty RN, Gardin JM, Hobbs FDR, McMurray JJV, Nagueh SF, et al. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function. JACC Cardiovasc Imaging 2015;8:656–65. https://doi.org/10.1016/j.jcmg.2015.02.014

87. Muraru D, Badano LP, Peluso D, Dal Bianco L, Casablanca S, Kocabay G, et al. Comprehensive Analysis of Left Ventricular Geometry and Function by ThreeDimensional Echocardiography in Healthy Adults. J Am Soc Echocardiogr 2013;26:618–28. https://doi.org/10.1016/j.echo.2013.03.014

88. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Hear J - Cardiovasc Imaging 2014;15:680–90. https://doi.org/10.1093/ehjci/jet284

89. Russell K, Eriksen M, Aaberge L, Wilhelmsen N, Skulstad H, Remme EW, et al. A novel clinical method for quantification of regional left ventricular pressurestrain loop area: a non-invasive index of myocardial work. Eur Heart J 2012;33:724–33. https://doi.org/10.1093/eurheartj/ehs016.

90. Сафиуллина АА, Ускач ТМ, Саидова МА, Добровольская СВ, Терещенко СН. Новые подходы к оценке сократительной функции левого желудочка у пациентов с хронической сердечной недостаточностью на фоне модуляции сердечной сократимости. Кародиологический вестник 2020;3:4–13. https://doi.org/10.36396/MS.2020.16.3.001

91. Wang C-L, Chan Y-H, Wu VC-C, Lee H-F, Hsiao F-C, Chu P-H. Incremental prognostic value of global myocardial work over ejection fraction and global longitudinal strain in patients with heart failure and reduced ejection fraction. Eur Hear J - Cardiovasc Imaging 2021;22:348–56. https://doi.org/10.1093/ehjci/jeaa162

92. Hedwig F, Nemchyna O, Stein J, Knosalla C, Merke N, Knebel F, et al. Myocardial Work Assessment for the Prediction of Prognosis in Advanced Heart Failure. Front Cardiovasc Med 2021;8. https://doi.org/10.3389/fcvm.2021.691611

93. Galli E, Hubert A, Le Rolle V, Hernandez A, Smiseth OA, Mabo P, et al. Myocardial constructive work and cardiac mortality in resynchronization therapy candidates. Am Heart J 2019;212:53–63. https://doi.org/10.1016/j.ahj.2019.02.008

94. Galli E, Leclercq C, Hubert A, Bernard A, Smiseth OA, Mabo P, et al. Role of myocardial constructive work in the identification of responders to CRT. Eur Hear J - Cardiovasc Imaging 2018;19:1010–8. https://doi.org/10.1093/ehjci/jex191

95. Gélinas R, Mailleux F, Dontaine J, Bultot L, Demeulder B, Ginion A, et al. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun 2018;9:374. https://doi.org/10.1038/s41467-017-02795-4

96. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314. https://doi.org/10.1016/j.echo.2016.01.011

97. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–317. https://doi.org/10.1093/eurheartj/ehz641

98. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, EvidenceBased Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 2018;138:861–70. https://doi.org/10.1161/CIRCULATIONAHA.118.034646

99. Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, et al. EchoDoppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. Eur Hear J - Cardiovasc Imaging 2017;18:961–8. https://doi.org/10.1093/ehjci/jex067

100. Senni M, Rodeheffer RJ, Tribouilloy CM, Evans JM, Jacobsen SJ, Bailey KR, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol 1999;33:164–70. https://doi.org/10.1016/S0735-1097(98)00523-3

101. Agha SA, Kalogeropoulos AP, Shih J, Georgiopoulou V V., Giamouzis G, Anarado P, et al. Echocardiography and Risk Prediction in Advanced Heart Failure: Incremental Value Over Clinical Markers. J Card Fail 2009;15:586–92. https://doi.org/10.1016/j.cardfail.2009.03.002

102. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017;135. https://doi.org/10.1161/CIR.0000000000000503

103. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911–39. https://doi.org/10.1016/j.echo.2014.07.012

104. Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE, Olson JJ, et al. Guidelines for the Use of Echocardiography as a Monitor for Therapeutic Intervention in Adults: A Report from the American Society of Echocardiography. J Am Soc Echocardiogr 2015;28:40–56. https://doi.org/10.1016/j.echo.2014.09.009

105. Hoffmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke C, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005;26:607–16. https://doi.org/10.1093/eurheartj/ehi083

106. Hoffmann R, Barletta G, von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C, et al. Analysis of Left Ventricular Volumes and Function: A Multicenter Comparison of Cardiac Magnetic Resonance Imaging, Cine Ventriculography, and Unenhanced and Contrast-Enhanced Two-Dimensional and Three-Dimensional Echocardiography. J Am Soc Echocardiogr 2014;27:292–301. https://doi.org/10.1016/j.echo.2013.12.005

107. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-Dimensional Echocardiography in Measuring Left Ventricular Volumes and Ejection Fraction. J Am Coll Cardiol 2012;59:1799–808. https://doi.org/10.1016/j.jacc.2012.01.037

108. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, et al. Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;124:1527–36. https://doi.org/10.1161/CIRCULATIONAHA.110.014324

109. Thavendiranathan P, Liu S, Datta S, Walls M, Nitinunu A, Van Houten T, et al. Automated Quantification of Mitral Inflow and Aortic Outflow Stroke Volumes by Three-Dimensional Real-Time Volume Color-Flow Doppler Transthoracic Echocardiography: Comparison with Pulsed-Wave Doppler and Cardiac Magnetic Resonance Imaging. J Am Soc Echocardiogr 2012;25:56–65. https://doi.org/10.1016/j.echo.2011.10.004

110. Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy. J Am Coll Cardiol 2014;63:2751–68. https://doi.org/10.1016/j.jacc.2014.01.073

111. Mignot A, Donal E, Zaroui A, Reant P, Salem A, Hamon C, et al. Global Longitudinal Strain as a Major Predictor of Cardiac Events in Patients with Depressed Left Ventricular Function: A Multicenter Study. J Am Soc Echocardiogr 2010;23:1019–24. https://doi.org/10.1016/j.echo.2010.07.019

112. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal Ranges of Left Ventricular Strain: A Meta-Analysis. J Am Soc Echocardiogr 2013;26:185–91. https://doi.org/10.1016/j.echo.2012.10.008

113. Stanton T, Leano R, Marwick TH. Prediction of All-Cause Mortality From Global Longitudinal Speckle Strain. Circ Cardiovasc Imaging 2009;2:356–64. https:// doi.org/10.1161/CIRCIMAGING.109.862334

114. Bansal M, Cho G-Y, Chan J, Leano R, Haluska BA, Marwick TH. Feasibility and Accuracy of Different Techniques of Two-Dimensional Speckle Based Strain and Validation With Harmonic Phase Magnetic Resonance Imaging. J Am Soc Echocardiogr 2008;21:1318–25. https://doi.org/10.1016/j.echo.2008.09.021

115. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–9. https://doi.org/10.1093/eurjhf/hfn013

116. Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, et al. Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2015;66:2092–100. https://doi.org/10.1016/j.jacc.2015.08.882

117. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014;35:2541–619. https://doi.org/10.1093/eurheartj/ehu278

118. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–77. https://doi.org/10.1093/eurheartj/ehz425

119. Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van `t Veer M, et al. Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. N Engl J Med 2009;360:213–24. https://doi.org/10.1056/NEJMoa0807611

120. Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, et al. Fractional Flow Reserve–Guided Versus Angiography-Guided Coronary Artery Bypass Graft Surgery. Circulation 2013;128:1405–11. https://doi.org/10.1161/CIRCULATIONAHA.113.002740

121. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. CoronaryArtery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med 2011;364:1607–16. https://doi.org/10.1056/NEJMoa1100356

122. Beller GA, Heede RC. SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability. J Cardiovasc Transl Res 2011;4:416–24. https://doi.org/10.1007/s12265-011-9290-2

123. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. J Am Coll Cardiol 2007;50:2002–12. https://doi.org/10.1016/j.jacc.2007.09.006

124. Angelidis G, Giamouzis G, Karagiannis G, Butler J, Tsougos I, Valotassiou V, et al. SPECT and PET in ischemic heart failure. Heart Fail Rev 2017;22:243–61. https://doi.org/10.1007/s10741-017-9594-7

125. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145. https://doi.org/10.1161/CIR.0000000000001039

126. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–94. https://doi.org/10.1093/eurheartj/ehv338

127. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-Related Subclinical Amyloidosis With 99mTc-DPD Scintigraphy. JACC Cardiovasc Imaging 2014;7:531–2. https://doi.org/10.1016/j.jcmg.2014.03.004

128. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99m TcPyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging 2013;6:195–201. https://doi.org/10.1161/CIRCIMAGING.112.000132

129. Seo M, Yamada T, Tamaki S, Watanabe T, Morita T, Furukawa Y, et al. Prognostic Significance of Cardiac 123I-MIBG SPECT Imaging in Heart Failure Patients With Preserved Ejection Fraction. JACC Cardiovasc Imaging 2022;15:655–68. https://doi.org/10.1016/j.jcmg.2021.08.003

130. Paeng JC, Choi JY. Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/ CT, and Amyloid-Targeting PET. Nucl Med Mol Imaging (2010) 2021;55:61–70. https://doi.org/10.1007/s13139-020-00681-4

131. Joseph V, Julien HM, Bravo PE. Radionuclide Imaging of Cardiac Amyloidosis. PET Clin 2021;16:285–93. https://doi.org/10.1016/j.cpet.2020.12.010

132. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Hear Fail 2019;7:709–16. https://doi.org/10.1016/j.jchf.2019.04.010

133. AlJaroudi WA, Desai MY, Tang WHW, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271–83. https://doi.org/10.1007/s12350-013-9800-5

134. Piepoli MF, Conraads V, Corrà U, Dickstein K, Francis DP, Jaarsma T, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347–57. https://doi.org/10.1093/eurjhf/hfr017

135. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919–23

136. Kaminsky LA, Tuttle MS. Functional Assessment of Heart Failure Patients. Heart Fail Clin 2015;11:29–36. https://doi.org/10.1016/j.hfc.2014.08.002

137. Enright PL. The six-minute walk test. Respir Care 2003;48:783–5. PMID: 12890299.

138. Faggiano P, D’Aloia A, Gualeni A, Brentana L, Cas LD. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail 2004;6:687–91. https://doi.org/10.1016/j.ejheart.2003.11.024

139. Zielińska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic Value of the SixMinute Walk Test in Heart Failure Patients Undergoing Cardiac Surgery: A Literature Review. Rehabil Res Pract 2013;2013:1–5. https://doi.org/10.1155/2013/965494

140. Ingle L, Cleland JG, Clark AL. The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure. Biomed Res Int 2014;2014:1–7. https://doi.org/10.1155/2014/505969

141. Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med 2014;57:244–53. https://doi.org/10.1016/j.rehab.2014.03.004

142. Pollentier B, Irons SL, Benedetto CM, Dibenedetto A-M, Loton D, Seyler RD, et al. Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. Cardiopulm Phys Ther J 2010;21:13–21. PMID: 2046751.

143. Palau P, Domínguez E, Núñez E, Sanchis J, Santas E, Núñez J. Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: Useful for functional capacity assessment? Int J Cardiol 2016;203:800–2. https://doi.org/10.1016/j.ijcard.2015.11.074

144. Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM, McKelvie RS, et al. 6-Min Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary Exercise Testing in Ambulatory Outpatients With Systolic Heart Failure. J Am Coll Cardiol 2012;60:2653–61. https://doi.org/10.1016/j.jacc.2012.08.1010

145. Corrà U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJS, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role. Eur J Heart Fail 2014;16:929–41. https://doi.org/10.1002/ejhf.156

146. Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:3–15. https://doi.org/10.1002/ejhf.979

147. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. J Am Coll Cardiol 2007;50:1914–31. https://doi.org/10.1016/j.jacc.2007.09.008

148. Cooper LT, Berry GJ, Shabetai R. Idiopathic Giant-Cell Myocarditis — Natural History and Treatment. N Engl J Med 1997;336:1860–6. https://doi.org/10.1056/NEJM199706263362603

149. Saric M, Armour AC, Arnaout MS, Chaudhry FA, Grimm RA, Kronzon I, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr 2016;29:1–42. https://doi.org/10.1016/j.echo.2015.09.011

150. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J Am Soc Echocardiogr 2011;24:229–67. https://doi.org/10.1016/j.echo.2010.12.008

151. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/ AHA Guideline for the Management of Heart Failure. Circulation 2013 Oct 15;128(16):e240-327. https://doi.org/10.1161/CIR.0b013e31829e8776

152. Obokata M, Kane GC, Reddy YN V., Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction. Circulation 2017;135:825–38. https://doi.org/10.1161/CIRCULATIONAHA.116.024822

153. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, et al. Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J 2008;30:278–89. https://doi.org/10.1093/eurheartj/ehn492

154. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151–8. https://doi.org/10.1016/S0735-1097(02)01726-6

155. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of Therapeutic Benefit from Revascularization in Patients With Left Ventricular Systolic Dysfunction. Circ Cardiovasc Imaging 2013;6:363–72. https://doi.org/10.1161/CIRCIMAGING.112.000138

156. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. N Engl J Med 2011;364:1617–25. https://doi.org/10.1056/NEJMoa1100358

157. deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol 1995;75:191–4. https://doi.org/10.1016/S0002-9149(00)80078-8

158. Tribouilloy C, Lévy F, Rusinaru D, Guéret P, Petit-Eisenmann H, Baleynaud S, et al. Outcome After Aortic Valve Replacement for Low-Flow/Low-Gradient Aortic Stenosis Without Contractile Reserve on Dobutamine Stress Echocardiography. J Am Coll Cardiol 2009;53:1865–73. https://doi.org/10.1016/j.jacc.2009.02.026

159. Clavel M-A, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, et al. Predictors of Outcomes in Low-Flow, Low-Gradient Aortic Stenosis. Circulation 2008 Sep 30;118(14 Suppl):S234-42. https://doi.org/10.1161/CIRCULATIONAHA.107.757427

160. Garnier F, Eicher J, Jazayeri S, Bertaux G, Bouchot O, Aho L, et al. Usefulness and limitations of contractile reserve evaluation in patients with low‐flow, low‐gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail 2014;16:648–54. https://doi.org/10.1002/ejhf.78

161. Erdei T, Smiseth OA, Marino P, Fraser AG. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU‐FP7 MEDIA study group. Eur J Heart Fail 2014;16:1345–61. https://doi.org/10.1002/ejhf.184

162. Donal E, Lund LH, Oger E, Reynaud A, Schnell F, Persson H, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Hear J – Cardiovasc Imaging 2016 Jan;17(1):106-13. Epub 2015 Jun 16. PMID: 26082167. https://doi.org/10.1093/ehjci/jev144

163. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391–412. https://doi.org/10.1002/ejhf.1741

164. Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 2001;37:278–85. https://doi.org/10.1016/S0735-1097(00)01056-1

165. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949–3003. https://doi.org/10.1093/eurheartj/eht296

166. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37:267–315. https://doi.org/10.1093/eurheartj/ehv320

167. Sousa PA, Bettencourt N, Dias Ferreira N, Carvalho M, Leite D, Ferreira W, et al. Role of cardiac multidetector computed tomography in the exclusion of ischemic etiology in heart failure patients. Rev Port Cardiol 2014;33:629–36. https://doi.org/10.1016/j.repc.2014.02.028

168. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. J Cardiovasc Comput Tomogr 2022;16:54–122. https://doi.org/10.1016/j.jcct.2021.11.009

169. Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H, et al. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). Eur Hear J - Cardiovasc Imaging 2021;22:1083–90. https://doi.org/10.1093/ehjci/jeaa109

170. Ferreira JP, Rossignol P, Demissei B, Sharma A, Girerd N, Anker SD, et al. Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart 2018;104:606–13. https://doi.org/10.1136/heartjnl-2017-311750

171. Sechtem U, Pflugfelder P, Higgins CB. Quantification of cardiac function by conventional and cine magnetic resonance imaging. Cardiovasc Intervent Radiol 1987;10:365–73. https://doi.org/10.1007/BF02577347

172. Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, de Roos A. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology 1993;187:261–8. https://doi.org/10.1148/radiology.187.1.8451425

173. Reichek N. Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q 1991;7:255–74

174. Hudsmith† L, Petersen† S, Francis J, Robson M, Neubauer S. Normal Human Left and Right Ventricular and Left Atrial Dimensions Using Steady State Free Precession Magnetic Resonance Imaging. J Cardiovasc Magn Reson 2005;7:775–82. https://doi.org/10.1080/10976640500295516

175. Maceira A, Prasad S, Khan M, Pennell D. Normalized Left Ventricular Systolic and Diastolic Function by Steady State Free Precession Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson 2006;8:417–26. https://doi.org/10.1080/10976640600572889

176. Contaldi C, Capuano F, Romano L, Ranieri B, Ferrara F, Mirto G, et al. Cardiovascular Magnetic Resonance in Right Heart and Pulmonary Circulation Disorders. Heart Fail Clin 2021;17:57–75. https://doi.org/10.1016/j.hfc.2020.08.006

177. Pons-Lladó G, Carreras F, Borrás X, Palmer J, Llauger J, Bayés de Luna A. Comparison of Morphologic Assessment of Hypertrophic Cardiomyopathy by Magnetic Resonance Versus Echocardiographic Imaging. Am J Cardiol 1997;79:1651–6. https://doi.org/10.1016/S0002-9149(97)00216-6

178. Moon JCC. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004;90:645–9. https://doi.org/10.1136/hrt.2003.014969

179. Fattori R, Biagini E, Lorenzini M, Buttazzi K, Lovato L, Rapezzi C. Significance of Magnetic Resonance Imaging in Apical Hypertrophic Cardiomyopathy. Am J Cardiol 2010;105:1592–6. https://doi.org/10.1016/j.amjcard.2010.01.020

180. Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular magnetic resonance characterization of left ventricular non-compaction provides independent prognostic information in patients with incident heart failure or suspected cardiomyopathy. J Cardiovasc Magn Reson 2014;16:64. https://doi.org/10.1186/s12968-014-0064-2

181. Choi Y, Kim SM, Lee S-C, Chang S-A, Jang SY, Choe YH. Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria. J Cardiovasc Magn Reson 2016;18:24. https://doi.org/10.1186/s12968-016-0245-2

182. Mavrogeni SI, Markousis-Mavrogenis G, Vartela V, Manolopoulou D, Abate E, Hamadanchi A, et al. The pivotal role of cardiovascular imaging in the identification and risk stratification of non-compaction cardiomyopathy patients. Heart Fail Rev 2020;25:1007–15. https://doi.org/10.1007/s10741019-09898-8

183. Patel AR, Kramer CM. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. JACC Cardiovasc Imaging 2017;10:1180–93. https://doi.org/10.1016/j.jcmg.2017.08.005

184. Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in Cardiac and Pulmonary Sarcoidosis. J Am Coll Cardiol 2020;76:1878–901. https://doi.org/10.1016/j.jacc.2020.08.042

185. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 2020;22:17. https://doi.org/10.1186/s12968-020-00607-1

186. Hundley WG, Bluemke DA, Bogaert J, Flamm SD, Fontana M, Friedrich MG, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 2022;24:29. https://doi.org/10.1186/s12968-021-00827-z

187. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Hear J - Cardiovasc Imaging 2015;16:14–22. https://doi.org/10.1093/ehjci/jeu182

188. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. JAMA 2013;309:896. https://doi.org/10.1001/jama.2013.1363

189. Contaldi C, Dellegrottaglie S, Mauro C, Ferrara F, Romano L, Marra AM, et al. Role of Cardiac Magnetic Resonance Imaging in Heart Failure. Heart Fail Clin 2021;17:207–21. https://doi.org/10.1016/j.hfc.2021.01.001

190. Gonzalez JA, Kramer CM. Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance. Curr Heart Fail Rep 2015;12:276–83. https://doi.org/10.1007/s11897-015-0261-9

191. Yoshida A, Ishibashi‐Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takahama H, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 2013;15:166–75. https://doi.org/10.1093/eurjhf/hfs206

192. Abbasi SA, Ertel A, Shah R V, Dandekar V, Chung J, Bhat G, et al. Impact of cardiovascular magnetic resonance on management and clinical decisionmaking in heart failure patients. J Cardiovasc Magn Reson 2013;15:89. https://doi.org/10.1186/1532-429X-15-89

193. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, et al. Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis. JACC Cardiovasc Imaging 2012;5:513–24. https://doi.org/10.1016/j.jcmg.2011.11.022

194. Sobol I, Horn EM, Dele-Michael A, Lin FY, Yushak M, Islam F, et al. 123 Assessment of Unexplained Cardiomyopathy (CMP) — Clinical Utility of Delayed-Enhancement Cardiac Magnetic Resonance (DE-CMR) Compared to Endomyocardial Biopsy. J Hear Lung Transplant 2012;31:S50. https://doi.org/10.1016/j.healun.2012.01.127

195. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15:92. https://doi.org/10.1186/1532-429X-15-92

196. Karamitsos TD, Papanastasiou CA. Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis. JACC Cardiovasc Imaging 2020;13:81–2. https://doi.org/10.1016/j.jcmg.2019.04.011

197. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. J Am Coll Cardiol 2008;51:1022–30. https://doi.org/10.1016/j.jacc.2007.10.049

198. Nam B Da, Kim SM, Jung HN, Kim Y, Choe YH. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping. Int J Cardiovasc Imaging 2018;34:1769–77. https://doi.org/10.1007/s10554-018-1385-2

199. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 2015;132:1570–9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567

200. Karur GR, Robison S, Iwanochko RM, Morel CF, Crean AM, Thavendiranathan P, et al. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology 2018;288:398–406. https://doi.org/10.1148/radiol.2018172613

201. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circ Cardiovasc Imaging 2013;6:392–8. https://doi.org/10.1161/CIRCIMAGING.112.000070

202. Zhang J, Li Y, Xu Q, Xu B, Wang H. Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A Meta-Analysis. Can Respir J 2018;2018:1– 10. https://doi.org/10.1155/2018/7457369

203. Чазова И.Е., Агеев Ф.Т., Аксенова А.В., Виценя М.В., Гиляров М.Ю., Мартынюк Т.В., Панченко Е.П., Полтавская М.Г., Потиевская В.И., Трофимова О.П., Федоткина Ю.А. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022). Евразийский Кардиологический Журнал. 2022;(1):6-79. https://doi.org/10.38109/2225-1685-2022-1-6-79

204. Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, et al. Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy. JACC CardioOncology 2020;2:270–92. https://doi.org/10.1016/j.jaccao.2020.04.011

205. Kalb B, Indik JH, Ott P, Martin DR. MRI of patients with implanted cardiac devices. J Magn Reson Imaging 2018;47:595–603. https://doi.org/10.1002/jmri.25824

206. Weidman EK, Dean KE, Rivera W, Loftus ML, Stokes TW, Min RJ. MRI safety: a report of current practice and advancements in patient preparation and screening. Clin Imaging 2015;39:935–7. https://doi.org/10.1016/j.clinimag.2015.09.002

207. Tsai LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. RadioGraphics 2015;35:1722–37. https://doi.org/10.1148/rg.2015150108

208. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin M-F, Bertolotto M, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients. Eur Radiol 2018;28:2856–69. https://doi.org/10.1007/s00330-017-5247-4

209. Bensimhon D, Alali SA, Curran L, Gelbart E, Garman DWV, Taylor R, et al. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Hear Lung 2021;50:59–64. https://doi.org/10.1016/j.hrtlng.2020.07.003

210. Olesen ASO, Miger K, Fabricius-Bjerre A, Sandvang KD, Kjesbu IE, Sajadieh A, et al. Remote dielectric sensing to detect acute heart failure in patients with dyspnoea: a prospective observational study in the emergency department. Eur Hear J Open 2022;2. https://doi.org/10.1093/ehjopen/oeac073

211. Sattar Y, Suleiman A-RM, Mir T, Ullah W, Zghouzi M, Arshad J, et al. Trend of heart failure readmission prevention in remote dielectric sensing (ReDS) monitoring – a meta-analysis. J Am Coll Cardiol 2021;77:808. https://doi.org/10.1016/S0735-1097(21)02167-7

212. Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J, et al. External Validation of the H 2 F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. Circulation 2019;139:2377–9. https://doi.org/10.1161/CIRCULATIONAHA.118.038594

213. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145. https://doi.org/10.1161/CIR.0000000000001063

214. Barandiarán Aizpurua A, Sanders‐van Wijk S, Brunner‐La Rocca H, Henkens M, Heymans S, Beussink‐Nelson L, et al. Validation of the HFA‐PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:413–21. https://doi.org/10.1002/ejhf.1614

215. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. N Engl J Med 1991;325:293–302. https://doi.org/10.1056/NEJM199108013250501

216. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019;380:539–48. https://doi.org/10.1056/NEJMoa1812851

217. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England) 1999;353:9–13

218. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999;341:709–17. https://doi.org/10.1056/NEJM199909023411001

219. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003;349:1893–906. https://doi.org/10.1056/NEJMoa032292

220. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414–21. https://doi.org/10.1016/S0735-1097(02)02304-5

221. Dimopoulos K, Salukhe T V., Coats AJS, Mayet J, Piepoli M, Francis DP. Metaanalyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker). Int J Cardiol 2004;93:105–11. https://doi.org/10.1016/j.ijcard.2003.10.001

222. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

223. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413–24. https://doi.org/10.1056/NEJMoa2022190

224. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a metaanalysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819– 29. https://doi.org/10.1016/S0140-6736(20)31824-9

225. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 1996;334:1349–55. https://doi.org/10.1056/NEJM199605233342101.

226. Gattis WA, O’Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003;91:169–74. https://doi.org/10.1016/S0002-9149(02)03104-1

227. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077

228. CONSENSUS Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987;316:1429–35. https://doi.org/10.1056/NEJM198706043162301

229. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–6. PMID: 7654275.

230. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 1992;327:669–77. https://doi.org/10.1056/NEJM199209033271001

231. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 1995;333:1670–6. https://doi.org/10.1056/NEJM199512213332503

232. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet (London, England) 1993;342:821–8. PMID: 8104270.

233. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation 1999;100:2312–8. https://doi.org/10.1161/01.CIR.100.23.2312

234. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. N Engl J Med 1992;327:685–91. https://doi.org/10.1056/NEJM199209033271003

235. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England) 1999;353:2001–7. PMID: 10376614.

236. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med 2001;344:1651–8. https://doi.org/10.1056/NEJM200105313442201

237. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25. https://doi.org/10.1093/eurheartj/ehi115.

238. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13. https://doi.org/10.1016/S0140-6736(03)13800-7

239. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385–90. https://doi.org/10.1016/S0140-6736(00)04560-8

240. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009;30:2186–92. https://doi.org/10.1093/eurheartj/ehp323

241. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492

242. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003;348:1309–21. https://doi.org/10.1056/NEJMoa030207

243. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol 2005;46:425–31. https://doi.org/10.1016/j.jacc.2005.04.038

244. Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Fail 2006;8:295–301. https://doi.org/10.1016/j.ejheart.2005.11.008

245. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–51. https://doi.org/10.1056/NEJMoa040135

246. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149–58. https://doi.org/10.1016/S0167-5273(01)00600-3

247. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. In: Faris RF, editor. Cochrane Database Syst. Rev., Chichester, UK: John Wiley & Sons, Ltd; 2012 Feb 15:(2):CD003838. https://doi.org/10.1002/14651858.CD003838.pub3

248. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376–82. https://doi.org/10.1016/0735-1097(96)00161-1

249. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure*. Clin Pharmacol Ther 1995;57:601–9. https://doi.org/10.1016/0009-9236(95)90222-8

250. Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994;14:514–21. PMID: 7997385.

251. Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507–13. https://doi.org/10.1016/S1388-9842(02)00122-8

252. Fortuño A, Muñiz P, Ravassa S, Rodriguez JA, Fortuño MA, Zalba G, et al. Torasemide Inhibits Angiotensin II–Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats. Hypertension 1999;34:138–43. https://doi.org/10.1161/01.HYP.34.1.138

253. Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M, et al. Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure. Circ J 2003;67:384–90. https://doi.org/10.1253/circj.67.384

254. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6. https://doi.org/10.1016/S0140-6736(03)14284-5

255. McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71. https://doi.org/10.1016/S0140-6736(03)14283-3

256. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840–8. https://doi.org/10.1016/S0140-6736(09)61913-9

257. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–85. https://doi.org/10.1016/S0140-6736(10)61198-1

258. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102:11–22. https://doi.org/10.1007/s00392-012-0467-8

259. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, et al. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? J Am Coll Cardiol 2012;59:1938–45. https://doi.org/10.1016/j.jacc.2012.01.020

260. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807–16. https://doi.org/10.1016/S0140-6736(08)61170-8

261. HOBBS RE. Digoxin’s effect on mortality and hospitalization in heart failure: implications of the DIG study. Cleve Clin J Med 1997;64:234–327. https://doi.org/10.3949/ccjm.64.5.234

262. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JGF, Butler J, Epstein AE, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013;34:1489–97. https://doi.org/10.1093/eurheartj/eht120

263. Jorge E, Baptista R, Martins H, Saraiva F, Costa S, Vieira H, et al. Digoxin in advanced heart failure patients: A question of rhythm. Rev Port Cardiol 2013;32:303–10. https://doi.org/10.1016/j.repc.2012.11.007

264. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF, et al. Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013;15:551–9. https://doi.org/10.1093/eurjhf/hft010

265. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003;289:871. https://doi.org/10.1001/jama.289.7.871

266. Adams KF, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA, et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial. J Am Coll Cardiol 2005;46:497–504. https://doi.org/10.1016/j.jacc.2005.02.091

267. Malik A, Masson R, Singh S, Wu W-C, Packer M, Pitt B, et al. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2019;74:617–27. https://doi.org/10.1016/j.jacc.2019.05.064

268. Терещенко СН, Черемисина ИА, Сафиуллина АА. Возможности улучшения терапии хронической сердечной недостаточности по результатам многоцентрового наблюдательного исследования BYHEART. Терапевтический архив 2022;94(4):517-523. https://doi.org/10.26442/00403660.2022.04.201450 [Tereshchenko SN, Cheremisina IA, Safiullina AA. The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Ter Arkh 2022;94:517–23. (in Russ.) https://doi.org/10.26442/00403660.2022.04.201450]

269. Терещенко С.Н., Черемисина И.А., Сафиуллина А.А. Эффективность неотона у больных с хронической сердечной недостаточностью в зависимости от фракции выброса левого желудочка. Субанализ исследования BYHEART. Российский кардиологический журнал. 2022;27(11):5276. https://doi.org/10.15829/1560-4071-2022-5276

270. Grazioli I, Melzi G, Strumia E. Multicenter controlled study of creatine phosphate in the treatment of heart failure. Curr Ther Res 1992;52:271–80. https://doi.org/10.1016/S0011-393X(05)80478-3

271. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. N Engl J Med 1986;314:1547–52. https://doi.org/10.1056/NEJM198606123142404

272. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004;351:2049–57. https://doi.org/10.1056/NEJMoa042934

273. Komajda M, McMurray JJV V, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824–31. https://doi.org/10.1093/eurheartj/ehp604

274. Hernandez A V., Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus. Am J Cardiovasc Drugs 2011;11:115–28. https://doi.org/10.2165/11587580-000000000-00000

275. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease. Diabetes Care 2007;30:2773–8. https://doi.org/10.2337/dc07-0717

276. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52–60. https:// doi.org/10.1161/01.CIR.83.1.52

277. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–6. https://doi.org/10.1016/S0140-6736(04)16299-5

278. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92:1610–5. https://doi.org/10.1136/hrt.2005.082388

279. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. N Engl J Med 1991;324:781–8. https://doi.org/10.1056/NEJM199103213241201

280. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235–43. https://doi.org/10.1016/S0140-6736(14)61373-8

281. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41–5. https://doi.org/10.1016/S1388-9842(99)00009-4

282. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990–7. https:// doi.org/10.1093/eurheartj/ehv186

283. Bonow RO, Castelvecchio S, Panza JA, Berman DS, Velazquez EJ, Michler RE, et al. Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. JACC Cardiovasc Imaging 2015;8:1121–9. https://doi.org/10.1016/j.jcmg.2015.03.013

284. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, et al. Inducible Myocardial Ischemia and Outcomes in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol 2013;61:1860–70. https://doi.org/10.1016/j.jacc.2013.02.014

285. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. N Engl J Med 2005;352:225–37. https://doi.org/10.1056/NEJMoa043399

286. Torp-Pedersen C, Metra M, Spark P, Lukas MA, Moullet C, Scherhag A, et al. The Safety of Amiodarone in Patients With Heart Failure. J Card Fail 2007;13:340–5. https://doi.org/10.1016/j.cardfail.2007.02.009

287. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia. N Engl J Med 1995;333:77–82. https://doi.org/10.1056/NEJM199507133330201

288. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart Failure Decompensation and All-Cause Mortality in Relation to Percent Biventricular Pacing in Patients With Heart Failure. J Am Coll Cardiol 2009;53:355–60. https://doi.org/10.1016/j.jacc.2008.09.043

289. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu T-Y, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Hear Rhythm 2010;7:865–9. https://doi.org/10.1016/j.hrthm.2010.03.036

290. Penela D, Van Huls Vans Taxis C, Aguinaga L, Fernández-Armenta J, Mont L, Castel MA, et al. Neurohormonal, Structural, and Functional Recovery Pattern After Premature Ventricular Complex Ablation Is Independent of Structural Heart Disease Status in Patients With Depressed Left Ventricular Ejection Fraction. J Am Coll Cardiol 2013;62:1195–202. https://doi.org/10.1016/j.jacc.2013.06.012

291. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, et al. Reversal of Cardiomyopathy in Patients With Repetitive Monomorphic Ventricular Ectopy Originating From the Right Ventricular Outflow Tract. Circulation 2005;112:1092–7. https://doi.org/10.1161/CIRCULATIONAHA.105.546432

292. Berruezo A, Penela D, Jáuregui B, Soto-Iglesias D, Aguinaga L, Ordóñez A, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. EP Eur 2019;21:1079–87. https://doi.org/10.1093/europace/euz027

293. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Hear Rhythm 2020;17:e2–154. https://doi.org/10.1016/j.hrthm.2019.03.002

294. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. Circulation 2002;106:2194–9. https://doi.org/10.1161/01.CIR.0000035653.72855.BF

295. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006 Jan 11;295(2):165-71. https://doi.org/10.1001/jama.295.2.165

296. A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. N Engl J Med 1997;337:1576–84. https://doi.org/10.1056/NEJM199711273372202

297. Connolly S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071–8. https://doi.org/10.1053/euhj.2000.2476

298. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS). Circulation 2000;101:1297–302. https://doi.org/10.1161/01.CIR.101.11.1297

299. Kuck K-H, Cappato R, Siebels J, Rüppel R. Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest. Circulation 2000;102:748–54. https://doi.org/10.1161/01.CIR.102.7.748

300. Oscar O, Enrique R, Andres B. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004;19:26–30. https://doi.org/10.1097/00001573-200401000-00007

301. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 2016;375:111–21. https://doi.org/10.1056/NEJMoa1513614

302. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med 2017;377:41–51. https:// doi.org/10.1056/NEJMoa1609758

303. Atti V, Vuddanda V, Turagam MK, Vemula P, Shah Z, Nagam H, et al. Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol 2018;53:207–15. https://doi.org/10.1007/s10840-018-0376-5

304. Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverterdefibrillators: A systematic review and meta-analysis of randomized controlled trials. Hear Rhythm 2016;13:1552–9. https://doi.org/10.1016/j.hrthm.2016.03.004

305. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al. Radiofrequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J 2014;35:1479–85. https://doi.org/10.1093/eurheartj/ehu040

306. Clemens M, Peichl P, Wichterle D, Pavlů L, Čihák R, Aldhoon B, et al. Catheter Ablation of Ventricular Tachycardia as the First‐Line Therapy in Patients With Coronary Artery Disease and Preserved Left Ventricular Systolic Function: Long‐Term Results. J Cardiovasc Electrophysiol 2015;26:1105–10. https://doi.org/10.1111/jce.12751

307. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy. JACC Hear Fail 2017;5:28–38. https://doi.org/10.1016/j.jchf.2016.09.017

308. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy. Circulation 2021;143:1343–58. https://doi.org/10.1161/CIRCULATIONAHA.120.048477

309. Francone M. Role of Cardiac Magnetic Resonance in the Evaluation of Dilated Cardiomyopathy: Diagnostic Contribution and Prognostic Significance. ISRN Radiol 2014;2014:1–16. https://doi.org/10.1155/2014/365404

310. Link MS, Costeas XF, Griffith JL, Colburn CD, Estes NAM, Wang PJ. High Incidence of Appropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Syncope of Unknown Etiology and Inducible Ventricular Arrhythmias. J Am Coll Cardiol 1997;29:370–5. https://doi.org/10.1016/S0735-1097(96)00477-9

311. Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden Cardiac Death Risk Stratification in Patients With Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol 2014;63:1879–89. https://doi.org/10.1016/j.jacc.2013.12.021

312. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Hear Rhythm 2015;12:1997–2007. https://doi.org/10.1016/j.hrthm.2015.05.036

313. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al. Outcomes in Catheter Ablation of Ventricular Tachycardia in Dilated Nonischemic Cardiomyopathy Compared With Ischemic Cardiomyopathy. Circulation 2014;129:728–36. https://doi.org/10.1161/CIRCULATIONAHA.113.003063

314. Muser D, Santangeli P, Castro SA, Pathak RK, Liang JJ, Hayashi T, et al. Long-Term Outcome After Catheter Ablation of Ventricular Tachycardia in Patients With Nonischemic Dilated Cardiomyopathy. Circ Arrhythmia Electrophysiol 2016;9. https://doi.org/10.1161/CIRCEP.116.004328

315. Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA, et al. Prevalence and Prognostic Impact of Pathogenic Variants in Patients With Dilated Cardiomyopathy Referred for Ventricular Tachycardia Ablation. JACC Clin Electrophysiol 2020;6:1103–14. https://doi.org/10.1016/j.jacep.2020.04.025

316. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle Branch Reentrant Ventricular Tachycardia: J Cardiovasc Electrophysiol 1993;4:253–62. https://doi.org/10.1111/j.1540-8167.1993.tb01228.x

317. Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:256–70. https://doi.org/10.1161/01.CIR.79.2.256

318. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, et al. Substrateguided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace 2015;17:461–7. https://doi.org/10.1093/europace/euu326

319. Tchou P, Jazayeri M, Denker S, Dongas J, Caceres J, Akhtar M. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988;78:246–57. https://doi.org/10.1161/01.CIR.78.2.246

320. Tzou WS, Tung R, Frankel DS, Vaseghi M, Bunch TJ, Di Biase L, et al. Ventricular Tachycardia Ablation in Severe Heart Failure. Circ Arrhythmia Electrophysiol 2017;10. https://doi.org/10.1161/CIRCEP.116.004494

321. Lee A, Denman R, Haqqani HM. Ventricular Ectopy in the Context of Left Ventricular Systolic Dysfunction: Risk Factors and Outcomes Following Catheter Ablation. Hear Lung Circ 2019;28:379–88. https://doi.org/10.1016/j.hlc.2018.01.012

322. Mountantonakis SE, Frankel DS, Gerstenfeld EP, Dixit S, Lin D, Hutchinson MD, et al. Reversal of outflow tract ventricular premature depolarization– induced cardiomyopathy with ablation: Effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Hear Rhythm 2011;8:1608–14. https://doi.org/10.1016/j.hrthm.2011.04.026

323. Oomen AWGJ, Dekker LRC, Meijer A. Catheter ablation of symptomatic idiopathic ventricular arrhythmias. Netherlands Hear J 2018;26:210–6. https://doi.org/10.1007/s12471-018-1085-5

324. Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction–induced cardiomyopathy. Hear Rhythm 2018;15:159–63. https://doi.org/10.1016/j.hrthm.2017.12.018

325. Køber L, Torp-Pedersen C, McMurray JJV, Gøtzsche O, Lévy S, Crijns H, et al. Increased Mortality after Dronedarone Therapy for Severe Heart Failure. N Engl J Med 2008;358:2678–87. https://doi.org/10.1056/NEJMoa0800456

326. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J 1992;13:1251–8

327. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038

328. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286

329. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive metaanalysis of five randomised controlled trials. Lancet 2022;400:757–67. https://doi.org/10.1016/S0140-6736(22)01429-5

330. Cleland JGF, Bunting K V, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35. https://doi.org/10.1093/eurheartj/ehx564

331. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015;131:34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255

332. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017;19:1258–69. https://doi.org/10.1002/ejhf.807

333. Solomon SD, Vaduganathan M, L. Claggett B, Packer M, Zile M, Swedberg K, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 2020;141:352–61. https://doi.org/10.1161/CIRCULATIONAHA.119.044586

334. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation 2020;142:1236–45. https://doi.org/10.1161/CIRCULATIONAHA.120.047643

335. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ V, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (London, England) 2003;362:777–81. https://doi.org/10.1016/S0140-6736(03)14285-7

336. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014;370:1383–92. https://doi.org/10.1056/NEJMoa1313731

337. Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2018;3:1000. https://doi.org/10.1001/jamacardio.2018.2568

338. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962. https://doi.org/10.1093/eurheartj/ehw210

339. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14:1030–40. https://doi.org/10.1093/eurjhf/hfs097

340. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005;26:1303–8. https://doi.org/10.1093/eurheartj/ehi166

341. Hoppe UC, Casares JM, Eiskjær H, Hagemann A, Cleland JGF, Freemantle N, et al. Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure. Circulation 2006;114:18–25. https://doi.org/10.1161/CIRCULATIONAHA.106.614560

342. Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol 2013;168:4093–7. https://doi.org/10.1016/j.ijcard.2013.07.017

343. Morris PD, Robinson T, Channer KS. Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities. Postgrad Med J 2012;88:706–12. https://doi.org/10.1136/postgradmedj-2011-130698

344. Голицын С.П., Панченко Е.П., Кропачева Е.С., Лайович Л.Ю., Майков Е.Б., Миронов Н.Ю., Шахматова О.О. Диагностика и лечение фибрилляции предсердий. Евразийский Кардиологический Журнал. 2019;(4):4-85. https://doi.org/10.38109/2225-1685-2019-4-4-8 Golitsyn SP, Panchenko EP, Kropacheva ES, Layovich LY, Maikov EB, Mironov NY, et al. Eurasian clinical recommendations on diagnosis and treatment of atrial fibrillation. Eurasian Hear J 2019:4–85. (in Russ.) https://doi.org/10.38109/2225-1685-2019-4-4-85]

345. Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M, et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction. Circ Hear Fail 2015;8:871–9. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002285

346. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor A V., et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005;149:1106–11. https://doi.org/10.1016/j.ahj.2004.11.030

347. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. N Engl J Med 2002;347:1834–40. https://doi.org/10.1056/NEJMoa021375

348. Hofmann R, Steinwender C, Kammler J, Kypta A, Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006;110:27–32. https://doi.org/10.1016/j.ijcard.2005.06.048

349. Hofmann R. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. Heart 2000;84:635–635. https://doi.org/10.1136/heart.84.6.635

350. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction. Circulation 1999;100:376–80. https://doi.org/10.1161/01.CIR.100.4.376

351. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;151:985–91. https://doi.org/10.1016/j.ahj.2005.06.036

352. McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. J Am Coll Cardiol 2005;45:525–30. https://doi.org/10.1016/j.jacc.2004.09.076

353. Han M, Zhang Y, Sun S, Wang Z, Wang J, Xie X, et al. Renin–Angiotensin System Inhibitors Prevent the Recurrence of Atrial Fibrillation. J Cardiovasc Pharmacol 2013;62:405–15. https://doi.org/10.1097/FJC.0b013e3182a094a1

354. Martin RIR, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014;100:1506–10. https://doi.org/10.1136/heartjnl-2014-305482

355. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is Cardiac Resynchronization Therapy an Antiarrhythmic Therapy for Atrial Fibrillation? A Systematic Review and Meta-Analysis. Curr Cardiol Rep 2013;15:330. https://doi.org/10.1007/s11886-012-0330-6

356. Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572–5. https://doi.org/10.1016/0002-9149(87)90307-9

357. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation. Circulation 1998;98:2574–9. https://doi.org/10.1161/01.CIR.98.23.2574

358. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924–30. https:// doi.org/10.1136/hrt.2008.158931

359. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 2018;378:417–27. https://doi.org/10.1056/NEJMoa1707855

360. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device. Circulation 2016;133:1637–44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406

361. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. J Am Coll Cardiol 2017;70:1949–61. https://doi.org/10.1016/j.jacc.2017.08.041

362. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Moretz K, et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. Am Heart J 2018;199:192–9. https://doi.org/10.1016/j.ahj.2018.02.015

363. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2019;74:104–32. https://doi.org/10.1016/j.jacc.2019.01.011

364. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. EP Eur 2006;8:935–42. https://doi.org/10.1093/europace/eul106

365. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944–51. https://doi.org/10.1016/j.jacc.2003.07.020

366. Mareev Y, Cleland JGF. Should β-Blockers Be Used in Patients With Heart Failure and Atrial Fibrillation? Clin Ther 2015;37:2215–24. https://doi.org/10.1016/j.clinthera.2015.08.017

367. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. N Engl J Med 2010;362:1363–73. https://doi.org/10.1056/NEJMoa1001337

368. Mulder BA, Van Veldhuisen DJ, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M, et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study. Eur J Heart Fail 2013;15:1311– 8. https://doi.org/10.1093/eurjhf/hft093

369. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, et al. Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. JACC Hear Fail 2013;1:500–7. https://doi.org/10.1016/j.jchf.2013.06.003

370. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. N Engl J Med 2008;358:2667–77. https://doi.org/10.1056/NEJMoa0708789

371. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-Analysis of Cardiovascular Outcomes With Dronedarone in Patients With Atrial Fibrillation or Heart Failure. Am J Cardiol 2012;110:607–13. https://doi.org/10.1016/j.amjcard.2012.04.034.

372. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in High-Risk Permanent Atrial Fibrillation. N Engl J Med 2011;365:2268–76. https://doi.org/10.1056/NEJMoa1109867

373. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H, et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. J Am Coll Cardiol 2012;59:1598–603. https://doi.org/10.1016/j.jacc.2011.11.063

374. Capucci A. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66–73. https://doi.org/10.1053/euhj.1999.1734

375. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI94-101

376. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk 1995;2:107–17

377. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med 2012;366:1859–69. https://doi.org/10.1056/NEJMoa1202299

378. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med 2018;379:1332–42. https://doi.org/10.1056/NEJMoa1808848

379. Sulaica EM, Macaulay TE, Helbing RR, Abo-Aly M, Abdel-Latif A, Wanat MA. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev 2020;25:207–16. https://doi.org/10.1007/s10741-019-09818-w

380. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139–51. https://doi.org/10.1056/NEJMoa0905561

381. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981–92. https://doi.org/10.1056/NEJMoa1107039

382. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011;365:883– 91. https://doi.org/10.1056/NEJMoa1009638

383. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369:2093–104. https://doi.org/10.1056/NEJMoa1310907

384. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials. Eur J Heart Fail 2015;17:1192–200. https://doi.org/10.1002/ejhf.343

385. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. https://doi.org/10.1016/S0140-6736(13)62343-0

386. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–83. https://doi.org/10.1016/S0140-6736(10)61194-4

387. Shin SY, Han S, Kim J, Im S Il, Shim J, Ahn J, et al. Identification of Markers Associated With Development of Stroke in “Clinically Low‐Risk” Atrial Fibrillation Patients. J Am Heart Assoc 2019;8. https://doi.org/10.1161/JAHA.119.012697

388. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GYH. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410

389. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395

390. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41. https://doi.org/10.1161/01.CIR.89.2.635

391. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:1059–63. https://doi.org/10.1161/01.CIR.72.5.1059

392. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med 2013;369:1206–14. https://doi.org/10.1056/NEJMoa1300615

393. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evid 2023;2. https://doi.org/10.1056/EVIDoa2300067

394. Guimarães HP, Lopes RD, de Barros e Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJMoa2029603

395. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. J Thorac Cardiovasc Surg 2023;165:5867.e4. https://doi.org/10.1016/j.jtcvs.2021.01.127

396. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation 2017;135:1273–5. https://doi.org/10.1161/CIRCULATIONAHA.116.026714

397. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. Thromb Haemost 2016;115:1056–63. https://doi.org/10.1160/TH16-01-0007

398. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967–75

399. Lip GYH, Skjøth F, Overvad K, Rasmussen LH, Larsen TB. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. Clin Res Cardiol 2015;104:1088–96. https://doi.org/10.1007/s00392-015-0878-4

400. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339

401. Schmieder RE, Rockstroh JK. Efficacy and Tolerance of Low-Dose Loop Diuretics in Hypertension. Cardiology 1994;84:36–42. https://doi.org/10.1159/000176455

402. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O’Connor C, et al. Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC Hear Fail 2013;1:308–14. https://doi.org/10.1016/j.jchf.2013.04.004

403. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril. Circulation 1997;96:856–63. https://doi.org/10.1161/01.CIR.96.3.856

404. Dorszewski A, Gohmann E, Dorszewski B, Werner G, Kreuzer H, Figulla H. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensinconverting enzyme inhibitors is not beneficial: Results of a placebo-controlled, double-blind study. J Card Fail 1997;3:91–6. https://doi.org/10.1016/S1071-9164(97)90040-3

405. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. BMJ 1985;290:1861–5. https://doi.org/10.1136/bmj.290.6485.1861

406. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung 1988;38:190–3

407. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. J Hypertens 2018;36:1637–47. https://doi.org/10.1097/HJH.0000000000001777

408. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustainedrelease moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–67. https://doi.org/10.1016/S1388-9842(03)00163-6

409. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007;357:2248–61. https://doi.org/10.1056/NEJMoa0706201

410. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231–9. https://doi.org/10.1016/S0140-6736(08)61240-4

411. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337–45. https://doi.org/10.1093/eurheartj/ehp358

412. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: A systematic review and meta-analysis of randomized clinical trials. Int J Cardiol 2011;146:4–12. https://doi.org/10.1016/j.ijcard.2010.05.019

413. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GMC. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — The VASCO-angina study. Int J Cardiol 2013;168:1078–81. https://doi.org/10.1016/j.ijcard.2012.11.001

414. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814–21. https://doi.org/10.1016/j.ehj.2004.06.034

415. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278–86. https:// doi.org/10.1136/hrt.2010.208751

416. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. N Engl J Med 1996;335:1107–14. https://doi.org/10.1056/NEJM199610103351504

417. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–75. https://doi.org/10.1016/S0140-6736(02)08265-X

418. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of Ranolazine in Patients With Chronic Angina. J Am Coll Cardiol 2009;53:1510–6. https://doi.org/10.1016/j.jacc.2009.01.037

419. Kosiborod M, Arnold S V., Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina. J Am Coll Cardiol 2013;61:2038–45. https://doi.org/10.1016/j.jacc.2013.02.011

420. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. CoronaryArtery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016;374:1511–20. https://doi.org/10.1056/NEJMoa1602001

421. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive Heart Failure in Type 2 Diabetes. Diabetes Care 2001;24:1614–9. https://doi.org/10.2337/diacare.24.9.1614

422. Kannel WB. Diabetes and cardiovascular disease. The Framingham study. JAMA J Am Med Assoc 1979;241:2035–8. https://doi.org/10.1001/jama.241.19.2035

423. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2000;35:1628–37. https://doi.org/10.1016/S0735-1097(00)00582-9

424. van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease. Diabetes Care 2010;33:2084–9. https://doi.org/10.2337/dc10-0286

425. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The Incidence of Congestive Heart Failure in Type 2 Diabetes. Diabetes Care 2004;27:1879–84. https://doi.org/10.2337/diacare.27.8.1879

426. Zareini B, Rørth R, Holt A, Mogensen UM, Selmer C, Gislason G, et al. Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol 2019;18:79. https://doi.org/10.1186/s12933-019-0883-4

427. Crespo‐Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long‐Term Registry (<scp>ESCHF‐LT</scp>): 1‐year follow‐up outcomes and differences across regions. Eur J Heart Fail 2016;18:613–25. https://doi.org/10.1002/ejhf.566

428. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377–85. https://doi.org/10.1093/eurheartj/ehn153

429. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation 2017;135:724–35. https://doi.org/10.1161/CIRCULATIONAHA.116.024593

430. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation 2021;143:326–36. https://doi.org/10.1161/CIRCULATIONAHA.120.051783

431. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure. Circulation 2005;111:583–90. https://doi.org/10.1161/01.CIR.0000154542.13412.B1

432. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure. Diabetes Care 2005;28:2345–51. https://doi.org/10.2337/diacare.28.10.2345

433. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, et al. Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database. Diabetes Care 2010;33:1213–8. https://doi.org/10.2337/dc09-2227

434. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J-P, et al. Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. PLoS Med 2012;9:e1001204. https://doi.org/10.1371/journal.pmed.1001204

435. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917

436. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827

437. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L V., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247–57. https://doi.org/10.1056/NEJMoa1509225

438. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141

439. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841–51. https://doi.org/10.1056/NEJMoa1901118

440. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3

441. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) — a multicentre, double‐blind, randomised, placebo‐controlled trial. Eur J Heart Fail 2017;19:69–77. https://doi.org/10.1002/ejhf.657

442. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA 2016;316:500. https://doi.org/10.1001/jama.2016.10260

443. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:189. https://doi.org/10.1186/s12933-021-01366-8

444. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373:232–42. https://doi.org/10.1056/NEJMoa1501352

445. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA 2019;321:69. https:// doi.org/10.1001/jama.2018.18269

446. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiol 2016;1:126. https://doi.org/10.1001/jamacardio.2016.0103

447. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 2012;367:319–28. https://doi.org/10.1056/NEJMoa1203858

448. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. https://doi.org/10.1186/s12933-019-0960-8

449. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824–31. https://doi.org/10.1093/eurheartj/ehp604

450. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, openlabel trial. Lancet 2009;373:2125–35. https://doi.org/10.1016/S0140-6736(09)60953-3

451. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013;369:1317–26. https://doi.org/10.1056/NEJMoa1307684

452. Rutten FH, Moons KGM, Cramer M-JM, Grobbee DE, Zuithoff NPA, Lammers an-WJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005;331:1379. https://doi.org/10.1136/bmj.38664.661181.55

453. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013;34:2795–807. https://doi.org/10.1093/eurheartj/eht192

454. Brenner S, Güder G, Berliner D, Deubner N, Fröhlich K, Ertl G, et al. Airway obstruction in systolic heart failure – COPD or congestion? Int J Cardiol 2013;168:1910–6. https://doi.org/10.1016/j.ijcard.2012.12.083

455. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med 1998;92:1321–5. https://doi.org/10.1016/S0954-6111(98)90136-6

456. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983;143:429–33

457. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol 1987;17:207–9. https://doi.org/10.1016/0167-5273(87)90132-X

458. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009;11:684–90. https://doi.org/10.1093/eurjhf/hfp066

459. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 2011;105:S44–9. https://doi.org/10.1016/S0954-6111(11)70010-5

460. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2010;55:1780–7. https://doi.org/10.1016/j.jacc.2010.01.024

461. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD003566. PMID: 16235327; PMCID: PMC8719355. https://doi.org/10.1002/14651858.CD003566.pub2

462. Düngen H-D, Apostolović S, Inkrot S, Tahirović E, Töpper A, Mehrhof F, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011;13:670–80. https://doi.org/10.1093/eurjhf/hfr020

463. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. Int J Cardiol 2013;170:182–8. https://doi.org/10.1016/j.ijcard.2013.10.068

464. O’Meara E, Rouleau JL, White M, Roy K, Blondeau L, Ducharme A, et al. Heart Failure With Anemia. Circ Hear Fail 2014;7:773–81. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001100

465. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Ole kowskaFlorek W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 2014;35:2468–76. https:// doi.org/10.1093/eurheartj/ehu235

466. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009;361:2436–48. https://doi.org/10.1056/NEJMoa0908355

467. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30–8. https://doi.org/10.1093/eurheartj/ehr504

468. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–68. https://doi.org/10.1093/eurheartj/ehu385

469. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895–904. https://doi.org/10.1016/S0140-6736(20)32339-4

470. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9

471. Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis. ESC Hear Fail 2023;10:1473–80. https://doi.org/10.1002/ehf2.14310

472. Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis. Eur J Heart Fail 2023;25:528–37. https://doi.org/10.1002/ejhf.2810

473. Vukadinović D, Abdin A, Emrich I, Schulze PC, von Haehling S, Böhm M. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin Res Cardiol 2023;112:954–66. https://doi.org/10.1007/s00392-023-02207-2

474. Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis. Eur J Heart Fail 2023;25:1080–90. https://doi.org/10.1002/ejhf.2860

475. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2019;380:447–58. https://doi.org/10.1056/NEJMoa1810742

476. Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, et al. Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC Hear Fail 2021;9:518–27. https://doi.org/10.1016/j.jchf.2021.04.005

477. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. N Engl J Med 2013;368:1210–9. https://doi.org/10.1056/NEJMoa1214865

478. Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987;147:1227–30

479. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical Hypothyroidism and the Risk of Coronary Heart Disease: A Meta-Analysis. Am J Med 2006;119:541–51. https://doi.org/10.1016/j.amjmed.2005.09.028

480. Harjai KJ. Effects of Amiodarone on Thyroid Function. Ann Intern Med 1997;126:63. https://doi.org/10.7326/0003-4819-126-1-199701010-00009

481. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation 2015;131:1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777

482. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671–80. https://doi.org/10.1093/eurheartj/ehw022

483. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. J Am Coll Cardiol 2013;61:2355–62. https://doi.org/10.1016/j.jacc.2013.02.072

484. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol 2006;48:2258–62. https://doi.org/10.1016/j.jacc.2006.07.052

485. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 2017;35:870–7. https://doi.org/10.1200/JCO.2016.68.7830

486. Čelutkienė J, Pudil R, López‐Fernández T, Grapsa J, Nihoyannopoulos P, BerglerKlein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504–24. https://doi.org/10.1002/ejhf.1957

487. RuОl Cardiol 2006;48:1527–37. https://doi.org/10.1016/j.jacc.2006.06.055

488. Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annu Rev Med 1984;35:503–11. https://doi.org/10.1146/annurev.me.35.020184.002443

489. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469–80. PMID: 10213794.

490. Оol 2002;441:137–40. https://doi.org/10.1016/s0014-2999(02)01532-7

491. Gelbrich G, Störk S, Kreißl‐Kemmer S, Faller H, Prettin C, Heuschmann PU, et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study. Eur J Heart Fail 2014;16:1133–41. https://doi.org/10.1002/ejhf.150

492. Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 2011;12:194. https://doi.org/10.1186/1745-6215-12-194

493. de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA, et al. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study. Heart 2007;93:819–25. https://doi.org/10.1136/hrt.2006.095810

494. Tu R, Zeng Z, Zhong G, Wu W, Lu Y, Bo Z, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta‐analysis of randomized controlled trials. Eur J Heart Fail 2014;16:749–57. https://doi.org/10.1002/ejhf.101

495. Беграмбекова Ю.Л., Мареев В.Ю., Дробижев М.Ю. Школы для пациентов с сердечной недостаточностью. Есть ли шанс повлиять на депрессию и тревогу? Вторичный (POST-HOC) анализ исследования ШАНС (школа и амбулаторное наблюдение больных сердечной недостаточностью). Журнал Сердечная Недостаточность 2016;17(6):433–42. https://doi.org/10.18087/ rhfj.2016.6.2281 [Begrambekova YL, Mareev VY, Drobizhev MY. Disease management programs for the heart failure patients. Is there any chance to defeat depression and anxiety POST-HOC analysis of CHANCE trial (congestive heart failure: a multidisciplinary non-pharmacological approach for changing in re-hospitalizat. Russ Hear Fail J 2016;6(17):433–42. (in Russ.) https://doi.org/10.18087/rhfj.2016.6.2281]

496. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. J Am Coll Cardiol 2010;56:692–9. https://doi.org/10.1016/j.jacc.2010.03.068

497. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression. JAMA 2016;315:2683. https://doi.org/10.1001/jama.2016.7635

498. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric Acid and Survival in Chronic Heart Failure. Circulation 2003;107:1991–7. https://doi.org/10.1161/01.CIR.0000065637.10517.A0

499. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Недогода С.В., Подзолков В.И., Ощепкова Е.В., Медведева И.В., Миронова О.Ю., Блинова Н.В. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019;16(4):8-21. https://doi.org/10.26442/2075082X.2019.4.190686

500. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation 2015;131:1763–71. https://doi.org/10.1161/CIRCULATIONAHA.114.014536

501. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018;378:1200–10. https://doi.org/10.1056/NEJMoa1710895

502. Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2015;15:96. https://doi.org/10.1186/s12872-015-0068-3

503. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Nonsteroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016:i4857. https://doi.org/10.1136/bmj.i4857

504. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, WaddingtonCruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018;379:1007–16. https://doi.org/10.1056/NEJMoa1805689

505. Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy. Clin Med Insights Cardiol 2017;11:117954681773032. https://doi.org/10.1177/1179546817730322

506. Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol 2018;25:464–8. https://doi.org/10.1111/ene.13510

507. Damy T, Garcia‐Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021;23:277–85. https://doi.org/10.1002/ejhf.2027

508. Heiat A, Gross CP, Krumholz HM. Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials. Arch Intern Med 2002;162. https://doi.org/10.1001/archinte.162.15.1682

509. Seo W-W, Park JJ, Park HA, Cho H-J, Lee H-Y, Kim KH, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open 2020;10:e030514. https://doi.org/10.1136/bmjopen-2019-030514

510. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, et al. LongTerm Trends in the Incidence of and Survival with Heart Failure. N Engl J Med 2002;347:1397–402. https://doi.org/10.1056/NEJMoa020265

511. Park S, Ahn J-M, Kim TO, Park H, Kang D-Y, Lee PH, et al. Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol 2020;76:1395–406. https://doi.org/10.1016/j.jacc.2020.07.047

512. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, et al. Comparison of Five-Year Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fractions ≤50% Versus &gt;50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 2014;114:988–96. https://doi.org/10.1016/j.amjcard.2014.07.007

513. Gaudino M, Hameed I, Khan FM, Tam DY, Rahouma M, Yongle R, et al. Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. Eur J Cardio-Thoracic Surg 2021;59:293–301. https://doi.org/10.1093/ejcts/ezaa319

514. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction. Circulation 2016;133:2132–40. https://doi.org/10.1161/CIRCULATIONAHA.115.021168

515. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. N Engl J Med 2001;344:873–80. https://doi.org/10.1056/NEJM200103223441202

516. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. N Engl J Med 2005;352:1539–49. https://doi.org/10.1056/NEJMoa050496

517. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al. Prevention of Disease Progression by Cardiac Resynchronization Therapy in Patients With Asymptomatic or Mildly Symptomatic Left Ventricular Dysfunction. J Am Coll Cardiol 2009;54:1837–46. https://doi.org/10.1016/j.jacc.2009.08.011

518. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013;34:2592–9. https://doi.org/10.1093/eurheartj/eht160

519. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928–32. https://doi.org/10.1093/eurheartj/ehl099

520. Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, et al. Long‐term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization‐Heart Failure (CARE‐HF) trial. Eur J Heart Fail 2012;14:628–34. https://doi.org/10.1093/eurjhf/hfs055

521. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. CardiacResynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. N Engl J Med 2004;350:2140–50. https://doi.org/10.1056/NEJMoa032423

522. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547–56. https://doi.org/10.1093/eurheartj/eht290

523. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. CardiacResynchronization Therapy for Mild-to-Moderate Heart Failure. N Engl J Med 2010;363:2385–95. https://doi.org/10.1056/NEJMoa1009540

524. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. CardiacResynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med 2009;361:1329–38. https://doi.org/10.1056/NEJMoa0906431

525. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. N Engl J Med 2014;370:1694–701. https://doi.org/10.1056/NEJMoa1401426

526. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daubert C. Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. J Am Coll Cardiol 2008;52:1834–43. https://doi.org/10.1016/j.jacc.2008.08.027

527. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015;101:1800–6. https://doi.org/10.1136/heartjnl-2015-307634

528. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular Pacing for Atrioventricular Block and Systolic Dysfunction. N Engl J Med 2013;368:1585–93. https://doi.org/10.1056/NEJMoa1210356.

529. Leclercq C. Comparative effects of permanent biventricular and right- univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002;23:1780–7. https://doi.org/10.1053/euhj.2002.3232

530. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a metaanalysis. Europace 2012;14:1490–7. https://doi.org/10.1093/europace/eus193

531. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011;97:740–7. https://doi.org/10.1136/hrt.2010.207340

532. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure. J Am Coll Cardiol 2013;61:1894–903. https://doi.org/10.1016/j.jacc.2013.01.069

533. Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac Resynchronization in Patients With Atrial Fibrillation. J Am Coll Cardiol 2008;52:1239–46. https://doi.org/10.1016/j.jacc.2008.06.043

534. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, et al. Benefits of Permanent His Bundle Pacing Combined With Atrioventricular Node Ablation in Atrial Fibrillation Patients With Heart Failure With Both Preserved and Reduced Left Ventricular Ejection Fraction. J Am Heart Assoc 2017;6. https://doi.org/10.1161/JAHA.116.005309

535. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:2420–9. https://doi.org/10.1093/eurheartj/ehr162

536. Gage RM, Burns K V., Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014;16:1199–205. https://doi.org/10.1002/ejhf.143

537. Funck RC, Mueller H-H, Lunati M, Piorkowski C, De Roy L, Paul V, et al. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). EP Eur 2014;16:354–62. https://doi.org/10.1093/europace/eut343

538. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, et al. Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study). J Cardiovasc Electrophysiol 2005;16:1160–5. https://doi.org/10.1111/j.1540-8167.2005.50062.x

539. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. CardiacResynchronization Therapy in Heart Failure with a Narrow QRS Complex. N Engl J Med 2013;369:1395–405. https://doi.org/10.1056/NEJMoa1306687

540. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015;36:1983–9. https://doi.org/10.1093/eurheartj/ehv242

541. Zusterzeel R, Selzman KA, Sanders WE, Caños DA, O’Callaghan KM, Carpenter JL, et al. Cardiac Resynchronization Therapy in Women. JAMA Intern Med 2014;174:1340. https://doi.org/10.1001/jamainternmed.2014.2717

542. Sohaib SMA, Finegold JA, Nijjer SS, Hossain R, Linde C, Levy WC, et al. Opportunity to Increase Life Span in Narrow QRS Cardiac Resynchronization Therapy Recipients by Deactivating Ventricular Pacing. JACC Hear Fail 2015;3:327–36. https://doi.org/10.1016/j.jchf.2014.11.007

543. Cleland JGF, Calvert MJ, Verboven Y, Freemantle N. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009;157:457–66. https://doi.org/10.1016/j.ahj.2008.11.006

544. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U, et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 2015;17:424–31. https://doi.org/10.1093/europace/euu205

545. Cleland JGF, Mareev Y, Linde C. Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?: Figure 1. Eur Heart J 2015;36:1948–51. https://doi.org/10.1093/eurheartj/ehv264

546. Daoulah A, Alsheikh-Ali AA, Al-Faifi SM, Ocheltree SR, Haq E, Asrar FM, et al. Cardiac resynchronization therapy in patients with postero-lateral scar by cardiac magnetic resonance: A systematic review and meta-analysis. J Electrocardiol 2015;48:783–90. https://doi.org/10.1016/j.jelectrocard.2015.06.012

547. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, et al. Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy. J Am Coll Cardiol 2012;59:1509–18. https://doi.org/10.1016/j.jacc.2011.12.030

548. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, et al. Echocardiography-Guided Left Ventricular Lead Placement for Cardiac Resynchronization Therapy. Circ Hear Fail 2013;6:427–34. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000078

549. Wikstrom G, Blomstrom-Lundqvist C, Andren B, Lonnerholm S, Blomstrom P, Freemantle N, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 2008;30:782–8. https://doi.org/10.1093/eurheartj/ehn577

550. Linde C, Abraham WT, Gold MR, Daubert JC, Tang ASL, Young JB, et al. Predictors of short‐term clinical response to cardiac resynchronization therapy. Eur J Heart Fail 2017;19:1056–63. https://doi.org/10.1002/ejhf.795

551. Strauss DG, Selvester RH, Wagner GS. Defining Left Bundle Branch Block in the Era of Cardiac Resynchronization Therapy. Am J Cardiol 2011;107:927–34. https://doi.org/10.1016/j.amjcard.2010.11.010

552. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;123:1061–72. https://doi.org/10.1161/CIRCULATIONAHA.110.960898

553. Chung ES, Leon AR, Tavazzi L, Sun J-P, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation 2008;117:2608–16. https://doi.org/10.1161/CIRCULATIONAHA.107.743120

554. Kosmala W, Marwick TH. Meta-Analysis of Effects of Optimization of Cardiac Resynchronization Therapy on Left Ventricular Function, Exercise Capacity, and Quality of Life in Patients With Heart Failure. Am J Cardiol 2014;113:988–94. https://doi.org/10.1016/j.amjcard.2013.12.006

555. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, et al. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol 2018;71:2319–30. https://doi.org/10.1016/j.jacc.2018.02.048

556. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, Direct His-Bundle Pacing. Circulation 2000;101:869–77. https://doi.org/10.1161/01.CIR.101.8.869

557. Sharma PS, Dandamudi G, Herweg B, Wilson D, Singh R, Naperkowski A, et al. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: A multicenter experience. Hear Rhythm 2018;15:413–20. https://doi.org/10.1016/j.hrthm.2017.10.014

558. Vijayaraman P, Dandamudi G, Zanon F, Sharma PS, Tung R, Huang W, et al. Permanent His bundle pacing: Recommendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up. Hear Rhythm 2018;15:460–8. https://doi.org/10.1016/j.hrthm.2017.10.039

559. Giraldi F, Cattadori G, Roberto M, Carbucicchio C, Pepi M, Ballerini G, et al. Long-Term Effectiveness of Cardiac Resynchronization Therapy in Heart Failure Patients With Unfavorable Cardiac Veins Anatomy. J Am Coll Cardiol 2011;58:483–90. https://doi.org/10.1016/j.jacc.2011.02.065

560. Barba-Pichardo R, Manovel Sánchez A, Fernández-Gómez JM, Moriña-Vázquez P, Venegas-Gamero J, Herrera-Carranza M. Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator. EP Eur 2013;15:83–8. https://doi.org/10.1093/europace/eus228.

561. Occhetta E, Bortnik M, Magnani A, Francalacci G, Piccinino C, Plebani L, et al. Prevention of Ventricular Desynchronization by Permanent Para-Hisian Pacing After Atrioventricular Node Ablation in Chronic Atrial Fibrillation. J Am Coll Cardiol 2006;47:1938–45. https://doi.org/10.1016/j.jacc.2006.01.056

562. Narula OS. Longitudinal dissociation in the His bundle. Bundle branch block due to asynchronous conduction within the His bundle in man. Circulation 1977;56:996–1006. https://doi.org/10.1161/01.CIR.56.6.996

563. Upadhyay GA, Cherian T, Shatz DY, Beaser AD, Aziz Z, Ozcan C, et al. Intracardiac Delineation of Septal Conduction in Left Bundle-Branch Block Patterns. Circulation 2019;139:1876–88. https://doi.org/10.1161/CIRCULATIONAHA.118.038648

564. Lustgarten DL, Crespo EM, Arkhipova-Jenkins I, Lobel R, Winget J, Koehler J, et al. His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: A crossover design comparison. Hear Rhythm 2015;12:1548–57. https://doi.org/10.1016/j.hrthm.2015.03.048

565. Diaz JC, Sauer WH, Duque M, Koplan BA, Braunstein ED, Marín JE, et al. Left Bundle Branch Area Pacing Versus Biventricular Pacing as Initial Strategy for Cardiac Resynchronization. JACC Clin Electrophysiol 2023;9:1568–81. https:// doi.org/10.1016/j.jacep.2023.04.015

566. Yap S-C, Schaer BA, Bhagwandien RE, Kühne M, Dabiri Abkenari L, Osswald S, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart 2014;100:1188–92. https://doi.org/10.1136/heartjnl-2014-305535

567. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al. Appropriateness of Primary Prevention Implantable Cardioverter-Defibrillators at the Time of Generator Replacement. J Am Coll Cardiol 2014;63:2388–94. https://doi.org/10.1016/j.jacc.2014.03.025

568. Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J, Wegscheider K, et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial—a prospective multicentre study. Eur Heart J 2013;34:130–7. https://doi.org/10.1093/eurheartj/ehs177

569. Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NA 3rd, Link MS. Time‐Dependence of Appropriate Implantable Defibrillator Therapy in Patients with Ischemic Cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:784–9. https://doi.org/10.1111/j.1540-8167.2008.01111.x

570. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68–75. https://doi.org/10.1161/01.CIR.89.1.68

571. Søholm H, Lønborg J, Andersen MJ, Vejlstrup N, Engstrøm T, Møller JE, et al. Repeated echocardiography after first ever ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention – is it necessary? Eur Hear J Acute Cardiovasc Care 2015;4:528–36. https://doi.org/10.1177/2048872614556000

572. Daubert MA, White JA, Al-Khalidi HR, Velazquez EJ, Rao S V., Crowley AL, et al. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. Am Heart J 2020;223:87–97. https://doi.org/10.1016/j.ahj.2020.02.017

573. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, et al. Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome. JACC Clin Electrophysiol 2018;4:672–82. https://doi.org/10.1016/j.jacep.2017.12.015

574. Whinnett ZI, Francis DP, Denis A, Willson K, Pascale P, van Geldorp I, et al. Comparison of different invasive hemodynamic methods for AV delay optimization in patients with cardiac resynchronization therapy: Implications for clinical trial design and clinical practice. Int J Cardiol 2013;168:2228–37. https://doi.org/10.1016/j.ijcard.2013.01.216

575. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. N Engl J Med 2002;346:877–83. https://doi.org/10.1056/NEJMoa013474

576. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy. JAMA 2004;292:2874. https://doi.org/10.1001/jama.292.23.2874

577. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease. N Engl J Med 1999;341:1882–90. https://doi.org/10.1056/NEJM199912163412503

578. Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou C-K, Dilaveris P, Sideris S, et al. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940– 9. https://doi.org/10.1093/eurheartj/ehz260

579. Sanders GD, Hlatky MA, Owens DK. Cost-Effectiveness of Implantable Cardioverter–Defibrillators. N Engl J Med 2005;353:1471–80. https://doi.org/10.1056/NEJMsa051989

580. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. N Engl J Med 2004;351:2481–8. https://doi.org/10.1056/NEJMoa041489

581. Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J 2015;36:1676–88. https://doi.org/10.1093/eurheartj/ehv102

582. Ader F, De Groote P, Réant P, Rooryck‐Thambo C, Dupin‐Deguine D, Rambaud C, et al. FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlations. Clin Genet 2019;96:317–29. https://doi.org/10.1111/cge.13594

583. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 2017;106:127–39. https://doi.org/10.1007/s00392-016-1033-6

584. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol 2016;68:2440–51. https://doi.org/10.1016/j.jacc.2016.09.927

585. van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Aufiero S, Khan MAF, et al. RBM20 Mutations Induce an Arrhythmogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling. Circulation 2018;138:1330–42. https:// doi.org/10.1161/CIRCULATIONAHA.117.031947

586. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol 2019;74:1480–90. https://doi.org/10.1016/j.jacc.2019.06.072

587. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation 2019;140:293–302. https://doi.org/10.1161/CIRCULATIONAHA.118.039410

588. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. J Am Coll Cardiol 2012;59:493–500. https://doi.org/10.1016/j.jacc.2011.08.078

589. Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden‐Lucet F, Isnard R, et al. External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. Eur J Heart Fail 2019;21:253–4. https://doi.org/10.1002/ejhf.1384

590. Merchant FM, Jones P, Wehrenberg S, Lloyd MS, Saxon LA. Incidence of Defibrillator Shocks After Elective Generator Exchange Following Uneventful First Battery Life. J Am Heart Assoc 2014;3. https://doi.org/10.1161/JAHA.114.001289

591. Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis. J Hear Lung Transplant 2015;34:1305–9. https://doi.org/10.1016/j.healun.2015.04.004

592. Zishiri ET, Williams S, Cronin EM, Blackstone EH, Ellis SG, Roselli EE, et al. Early Risk of Mortality After Coronary Artery Revascularization in Patients With Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator. Circ Arrhythmia Electrophysiol 2013;6:117–28. https://doi.org/10.1161/CIRCEP.112.973552

593. Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, et al. Aggregate National Experience With the Wearable Cardioverter-Defibrillator. J Am Coll Cardiol 2010;56:194–203. https://doi.org/10.1016/j.jacc.2010.04.016

594. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J, ElChami MF, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med 2020;383:526–36. https://doi.org/10.1056/NEJMoa1915932

595. León Salas B, Trujillo‐Martín MM, García García J, Ramallo Fariña Y, García Quintana A, Quirós López R, et al. Subcutaneous implantable cardioverterdefibrillator in primary and secondary prevention of sudden cardiac death: A meta‐analysis. Pacing Clin Electrophysiol 2019;42:1253–68. https://doi.org/10.1111/pace.13774

596. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016;375:1221–30. https://doi.org/10.1056/NEJMoa1608029

597. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, et al. Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. JACC Hear Fail 2014;2:623–9. https://doi.org/10.1016/j.jchf.2014.06.007

598. Miller RJH, Howlett JG, Exner D V., Campbell PM, Grant ADM, Wilton SB. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. Can J Cardiol 2015;31:792–9. https://doi.org/10.1016/j.cjca.2014.12.031

599. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet (London, England) 1997;350:1417–24

600. Andrey JL, Gomez-Soto FM, Romero SP, Escobar MA, García-Egido AA, GarciaArjona R, et al. Mortality of newly diagnosed heart failure treated with amiodarone. Int J Cardiol 2011;151:175–81. https://doi.org/10.1016/j.ijcard.2010.05.012

601. Piepoli M, Villani GQ, Ponikowski P, Wright A, Flather MD, Coats AJ. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. Int J Cardiol 1998;66:1–10. https://doi.org/10.1016/S0167-5273(98)00184-3

602. Merlo M, Gentile P, Artico J, Cannatà A, Paldino A, De Angelis G, et al. Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction. J Cardiovasc Med 2019;20:343–50. https://doi.org/10.2459/JCM.0000000000000792

603. Zecchin M, Di Lenarda A, Gregori D, Merlo M, Pivetta A, Vitrella G, et al. Are Nonsustained Ventricular Tachycardias Predictive of Major Arrhythmias in Patients with Dilated Cardiomyopathy on Optimal Medical Treatment? Pacing Clin Electrophysiol 2008;31:290–9. https://doi.org/10.1111/j.1540-8159.2008.00988.x

604. Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol 2021;77:2890–905. https://doi.org/10.1016/j.jacc.2021.04.030

605. Theuns DAMJ, Smith T, Hunink MGM, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 2010;12:1564–70. https://doi.org/10.1093/europace/euq329

606. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator Implantation Early after Myocardial Infarction. N Engl J Med 2009;361:1427–36. https://doi.org/10.1056/NEJMoa0901889

607. Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, et al. Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circ Arrhythmia Electrophysiol 2014;7:793–9. https://doi.org/10.1161/CIRCEP.114.001455

608. Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K, et al. Patient Expectations From Implantable Defibrillators to Prevent Death in Heart Failure. J Card Fail 2010;16:106–13. https://doi.org/10.1016/j.cardfail.2009.09.003

609. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An Entirely Subcutaneous Implantable Cardioverter–Defibrillator. N Engl J Med 2010;363:36–44. https://doi.org/10.1056/NEJMoa0909545

610. Aziz S, Leon AR, El-Chami MF. The Subcutaneous Defibrillator. J Am Coll Cardiol 2014;63:1473–9. https://doi.org/10.1016/j.jacc.2014.01.018

611. Olde Nordkamp LRA, Knops RE, Bardy GH, Blaauw Y, Boersma LVA, Bos JS, et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J 2012;163:753-760.e2. https://doi.org/10.1016/j.ahj.2012.02.012

612. Burke MC, Gold MR, Knight BP, Barr CS, Theuns DAMJ, Boersma LVA, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. J Am Coll Cardiol 2015;65:1605–15. https://doi.org/10.1016/j.jacc.2015.02.047

613. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2015:euv319. https://doi.org/10.1093/europace/euv319

614. Abraham WT, Kuck K-H, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Hear Fail 2018;6:874–83. https://doi.org/10.1016/j.jchf.2018.04.010

615. Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, et al. Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure. J Card Fail 2011;17:710–7. https://doi.org/10.1016/j.cardfail.2011.05.006

616. Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011;161:329-337.e2. https://doi.org/10.1016/j.ahj.2010.10.025

617. Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008;29:1019–28. https://doi.org/10.1093/eurheartj/ehn020

618. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080–90. https://doi.org/10.1016/0003-4975(92)90393-I

619. Gustafsson F, Shaw S, Lavee J, Saeed D, Pya Y, Krabatsch T, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. Eur Heart J 2018;39:3454–60. https://doi.org/10.1093/eurheartj/ehy513

620. Strueber M, O’Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM. Multicenter Evaluation of an Intrapericardial Left Ventricular Assist System. J Am Coll Cardiol 2011;57:1375–82. https://doi.org/10.1016/j.jacc.2010.10.040

621. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the Destination Therapy Post-Food and Drug Administration Approval Study With a Continuous Flow Left Ventricular Assist Device. J Am Coll Cardiol 2014;63:1751–7. https://doi.org/10.1016/j.jacc.2014.01.053

622. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Hear Lung Transplant 2014;33:12–22. https://doi.org/10.1016/j.healun.2013.11.001

623. Mehra MR, Salerno C, Cleveland JC, Pinney S, Yuzefpolskaya M, Milano CA, et al. Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long- Term Outcome Study. Circulation 2018;138:1923–34. https://doi.org/10.1161/CIRCULATIONAHA.118.035722

624. Mehra MR, Uriel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, et al. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. N Engl J Med 2019;380:1618–27. https://doi.org/10.1056/NEJMoa1900486

625. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, et al. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF. J Am Coll Cardiol 2015;66:2579–89. https://doi.org/10.1016/j.jacc.2015.09.083

626. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, et al. The REMATCH trial: rationale, design, and end points. Ann Thorac Surg 1999;67:723–30. https://doi.org/10.1016/S0003-4975(99)00042-9

627. Schmitto JD, Hanke JS, Rojas S V., Avsar M, Haverich A. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Hear Lung Transplant 2015;34:858–60. https://doi.org/10.1016/j.healun.2015.03.001

628. Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB, et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. JACC Hear Fail 2017;5:518–27. https://doi.org/10.1016/j.jchf.2017.02.016

629. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure. J Am Coll Cardiol 2019;73:1430–43. https://doi.org/10.1016/j.jacc.2018.12.072

630. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise‐based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta‐analysis of randomised trials. Eur J Heart Fail 2018;20:1735–43. https://doi.org/10.1002/ejhf.1311

631. Pandey A, Parashar A, Kumbhani DJ, Agarwal S, Garg J, Kitzman D, et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circ Hear Fail 2015;8:33–40. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001615

632. Taylor RS, Long L, Mordi IR, Madsen MT, Davies EJ, Dalal H, et al. Exercise-Based Rehabilitation for Heart Failure. JACC Hear Fail 2019;7:691–705. https://doi.org/10.1016/j.jchf.2019.04.023

633. Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess (Rockv) 2019;23:1–98. https://doi.org/10.3310/hta23250

634. Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, et al. Effect of Endurance Exercise Training on Endothelial Function and Arterial Stiffness in Older Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2013;62:584–92. https://doi.org/10.1016/j.jacc.2013.04.033

635. Ismail H, McFarlane J, Smart NA. Is Exercise Training Beneficial for Heart Failure Patients Taking β‐Adrenergic Blockers? A Systematic Review and Meta‐ Analysis. Congest Hear Fail 2013;19:61–9. https://doi.org/10.1111/chf.12000

636. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction. JAMA 2016;315:36. https://doi.org/10.1001/jama.2015.17346

637. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercisebased rehabilitation for heart failure. Cochrane Database Syst Rev 2014 Apr 27;2014(4):CD003331. https://doi.org/10.1002/14651858.CD003331.pub4

638. Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical Outcomes and Cardiovascular Responses to Different Exercise Training Intensities in Patients With Heart Failure. JACC Hear Fail 2013;1:514–22. https://doi.org/10.1016/j.jchf.2013.08.006

639. Wang M-H, Yeh M-L. Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trails. World J Clin Cases 2019;7:2760–75. https://doi.org/10.12998/wjcc.v7.i18.2760

640. Adamopoulos S, Schmid J, Dendale P, Poerschke D, Hansen D, Dritsas A, et al. Combined aerobic/inspiratory muscle training vs. aerobic training in patients with chronic heart failure. Eur J Heart Fail 2014;16:574–82. https://doi.org/10.1002/ejhf.70

641. McAlister FA, Lawson FM., Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378–84. https://doi.org/10.1016/S0002-9343(00)00743-9

642. Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray JJV, Naylor MD, et al. What Works In Chronic Care Management: The Case Of Heart Failure. Health Aff 2009;28:179–89. https://doi.org/10.1377/hlthaff.28.1.179

643. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta‐analysis. Eur J Heart Fail 2017;19:1427–43. https://doi.org/10.1002/ejhf.765

644. Wakefield BJ, Boren SA, Groves PS, Conn VS. Heart Failure Care Management Programs. J Cardiovasc Nurs 2013;28:8–19. https://doi.org/10.1097/JCN.0b013e318239f9e1

645. Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, et al. Effect of PatientCentered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. JAMA 2019;321:753. https://doi.org/10.1001/jama.2019.0710

646. Feltner C, Jones CD, Cené CW, Zheng Z-J, Sueta CA, Coker-Schwimmer EJL, et al. Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure. Ann Intern Med 2014;160:774. https://doi.org/10.7326/M14-0083

647. Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ, et al. Randomized trial of an education and support intervention to preventreadmission of patients with heart failure. J Am Coll Cardiol 2002;39:83– 9. https://doi.org/10.1016/S0735-1097(01)01699-0

648. Organization of specialized medical care for patients with chronic heart failure. Cardiosomatics 2017;8:10–5. https://doi.org/10.26442/2221-7185_8.3.10-15

649. Фомин И.В., Виноградова Н.Г., Фарзалиев М.И., Аллахвердиева С.М., Крылова А.Н., Самарина А.С. Тюрин А.А. Эффективность наблюдения пациентов в условиях специализированного центра лечения хронической сердечной недостаточности. Неотложная Кардиология и Кардиоваскулярные Риски 2018;1(2):221–9.

650. Виноградова Н.Г., Поляков Д.С., Фомин И.В., Жиркова М.М. Прогноз жизни пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в зависимости от контроля гемодинамических показателей и толерантности к физической нагрузке на фоне базисной терапии. Кардиология. 2019;59(4S):51-58. https://doi.org/10.18087/cardio.2622

651. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1

652. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453–61. https://doi.org/10.1016/S0140-6736(15)00723-0

653. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991–1001. https://doi.org/10.1016/S0140-6736(21)01754-2

654. McAlister FA, Stewart S, Ferrua S, McMurray JJJV. Multidisciplinary strategies for the management of heart failure patients at high risk for admission. J Am Coll Cardiol 2004;44:810–9. https://doi.org/10.1016/j.jacc.2004.05.055

655. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive Discharge Planning With Postdischarge Support for Older Patients With Congestive Heart Failure. JAMA 2004;291:1358. https://doi.org/10.1001/jama.291.11.1358

656. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged Beneficial Effects of a Home-Based Intervention on Unplanned Readmissions and Mortality Among Patients With Congestive Heart Failure. Arch Intern Med 1999;159:257. https://doi.org/10.1001/archinte.159.3.257

657. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, et al. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J 2013;34:432–42. https://doi.org/10.1093/eurheartj/ehs235

658. Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW, et al. Longterm follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 2014;16:1241–8. https://doi.org/10.1002/ejhf.173

659. Bjork JB, Alton KK, Georgiopoulou V V., Butler J, Kalogeropoulos AP. Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. J Card Fail 2016;22:569–77. https://doi.org/10.1016/j.cardfail.2016.03.003

660. Harjola V, Mullens W, Banaszewski M, Bauersachs J, Brunner‐La Rocca H, Chioncel O, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:821–36. https://doi.org/10.1002/ejhf.872

661. Hummel YM, Liu LCY, Lam CSP, Fonseca‐Munoz DF, Damman K, Rienstra M, et al. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail 2017;19:1651–60. https://doi.org/10.1002/ejhf.957

662. Quiñones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. A list of participating hospitals, central agencies and personnel app. J Am Coll Cardiol 2000;35:1237–44. https://doi.org/10.1016/S0735-1097(00)00511-8

663. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. J Am Coll Cardiol 2004;43:2022–7. https://doi.org/10.1016/j.jacc.2003.12.053

664. Rossi A, Cicoira M, Bonapace S, Golia G, Zanolla L, Franceschini L, et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart 2007;93:1420–5. https://doi.org/10.1136/hrt.2006.101261

665. Paraskevaidis IA, Ikonomidis I, Simitsis P, Parissis J, Stasinos V, Makavos G, et al. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4‐year follow‐up study. Eur J Heart Fail 2017;19:846–61. https://doi.org/10.1002/ejhf.787

666. Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J 2016;37:1244–51. https://doi.org/10.1093/eurheartj/ehv745

667. Randolph TC, Broderick S, Shaw LK, Chiswell K, Mentz RJ, Kutyifa V, et al. Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. J Am Heart Assoc 2017;6. https://doi.org/10.1161/JAHA.116.004381

668. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal Impairment and Outcomes in Heart Failure. J Am Coll Cardiol 2006;47:1987–96. https://doi.org/10.1016/j.jacc.2005.11.084

669. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure. Circulation 2003;108:833–8. https://doi.org/10.1161/01.CIR.0000084543.79097.34

670. Nellessen U, Goder S, Schobre R, Abawi M, Hecker H, Tschöke S. Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin Cardiol 2006;29:219–24. https://doi.org/10.1002/clc.4960290510

671. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure. J Am Coll Cardiol 2007;49:1943–50. https://doi.org/10.1016/j.jacc.2007.02.037

672. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal proB-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011;13:718–25. https://doi.org/10.1093/eurjhf/hfr047

673. Wang NC. Clinical Implications of QRS Duration in Patients Hospitalized With Worsening Heart Failure and Reduced Left Ventricular Ejection Fraction. JAMA 2008;299:2656. https://doi.org/10.1001/jama.299.22.2656

674. Park M, Sangean MC, Volpe M de S, Feltrim MIZ, Nozawa E, Leite PF, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med 2004;32:2407–15. https://doi.org/10.1097/01.CCM.0000147770.20400.10

675. Perna ER, Macin SM, Canella JPC, Augier N, Stival JLR, Cialzeta JR, et al. Ongoing Myocardial Injury in Stable Severe Heart Failure. Circulation 2004;110:2376–82. https://doi.org/10.1161/01.CIR.0000145158.33801.F3

676. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, et al. Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal ProB-Type Natriuretic Peptide in Patients With Chronic Heart Failure. J Am Coll Cardiol 2008;52:266–72. https://doi.org/10.1016/j.jacc.2008.03.050

677. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJ V. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 2010;96:533–8. https://doi.org/10.1136/hrt.2009.175257

678. Weng C-L. Meta-analysis: Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema. Ann Intern Med 2010;152:590. https://doi.org/10.7326/0003-4819-152-9-201005040-00009

679. Gray A, Goodacre S, Newby D, Masson M, Sampson F, Dixon S, et al. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oe. Health Technol Assess (Rockv) 2009;13. https://doi.org/10.3310/hta13330

680. Vital FM, Ladeira MT, Atallah ÁN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013 May 31:(5):CD005351. https://doi.org/10.1002/14651858.CD005351.pub3

681. Berbenetz N, Wang Y, Brown J, Godfrey C, Ahmad M, Vital FM, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2019 Apr 5;4(4):CD005351. https://doi.org/10.1002/14651858.CD005351.pub4

682. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669–74. https://doi.org/10.1016/S0196-0644(05)82777-5

683. Metra M, Felker GM, Zacà V, Bugatti S, Lombardi C, Bettari L, et al. Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol 2010;144:175–9. https://doi.org/10.1016/j.ijcard.2010.04.003

684. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013 Aug 6;2013(8):CD005151. https://doi.org/10.1002/14651858.CD005151.pub2

685. Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I, et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail 2015;17:1182–91. https://doi.org/10.1002/ejhf.346

686. Agostoni P, Paolillo S, Mapelli M, Gentile P, Salvioni E, Veglia F, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison. Eur J Heart Fail 2018;20:700–10. https://doi.org/10.1002/ejhf.989

687. Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 2017;19:1414–23. https://doi.org/10.1002/ejhf.887

688. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017;19:627–34. https://doi.org/10.1002/ejhf.785

689. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol 2003;92:1350– 4. https://doi.org/10.1016/j.amjcard.2003.08.027

690. Wachter R, Senni M, Belohlavek J, Straburzynska‐Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998–1007. https://doi.org/10.1002/ejhf.1498

691. Thorvaldsen T, Benson L, Ståhlberg M, Dahlström U, Edner M, Lund LH. Triage of Patients With Moderate to Severe Heart Failure. J Am Coll Cardiol 2014;63:661–71. https://doi.org/10.1016/j.jacc.2013.10.017

692. Jonkman NH, Westland H, Groenwold RHH, Ågren S, Atienza F, Blue L, et al. Do Self-Management Interventions Work in Patients With Heart Failure? Circulation 2016;133:1189–98. https://doi.org/10.1161/CIRCULATIONAHA.115.018006

693. Lala A, Barghash MH, Giustino G, Alvarez‐Garcia J, Konje S, Parikh A, et al. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Hear Fail 2021;8:1047–54. https://doi.org/10.1002/ehf2.13026

694. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and betablockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38:1883–90. https://doi.org/10.1093/eurheartj/ehx026

695. Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. Med Care 2016;54:365–72. https://doi.org/10.1097/MLR.0000000000000492

696. Edmonston DL, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Piña IL, et al. Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. Am Heart J 2019;212:101–12. https://doi.org/10.1016/j.ahj.2019.03.005

697. Tromp J, Ponikowski P, Salsali A, Angermann CE, Biegus J, Blatchford J, et al. Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail 2021;23:826–34. https://doi.org/10.1002/ejhf.2137

698. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568–74. https:// doi.org/10.1038/s41591-021-01659-1

699. Iakobishvili Z, Cohen E, Garty M, Behar S, Shotan A, Sandach A, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care 2011;13:76–80. https://doi.org/10.3109/17482941.2011.575165

700. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008;25:205–9. https://doi.org/10.1136/emj.2007.050419

701. Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure. JAMA 2002;287. https://doi.org/10.1001/jama.287.12.1531

702. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl J Med 2011;364:797–805. https://doi.org/10.1056/NEJMoa1005419

703. Jentzer JC, DeWald TA, Hernandez AF. Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure. J Am Coll Cardiol 2010;56:1527–34. https://doi.org/10.1016/j.jacc.2010.06.034

704. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 2018;20:1591–600. https://doi.org/10.1002/ejhf.1307

705. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med 2022;387:1185–95. https://doi.org/10.1056/NEJMoa2203094

706. Hashim T, Sanam K, Revilla-Martinez M, Morgan CJ, Tallaj JA, Pamboukian S V., et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Hear Fail 2015;8:880–6. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001778

707. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. JACC Hear Fail 2013;1:103–11. https://doi.org/10.1016/j.jchf.2012.12.004

708. O’Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78–86. https://doi.org/10.1016/S0002-8703(99)70250-4

709. Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials. ESC Hear Fail 2017;4:595–604. https://doi.org/10.1002/ehf2.12177

710. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 2015;115:656–75. https://doi.org/10.1093/bja/aev284

711. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur Heart J 1995;16:521–8. https://doi.org/10.1093/oxfordjournals.eurheartj.a060945

712. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149–53. https://doi.org/10.1097/00003246-200106000-00011

713. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients. Ann Intern Med 2007;146:278. https://doi.org/10.7326/0003-4819-146-4-200702200-00007

714. Sintek MA, Gdowski M, Lindman BR, Nassif M, Lavine KJ, Novak E, et al. IntraAortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization. J Card Fail 2015;21:868–76. https://doi.org/10.1016/j.cardfail.2015.06.383

715. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med 2017;376:451–60. https://doi.org/10.1056/NEJMoa1602954

716. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Yuzefpolskaya M, Salerno C, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med 2018;378:1386–95. https://doi.org/10.1056/NEJMoa1800866